var title_f5_61_6096="Cryptogenic organizing pneumonia CXR III";
var content_f5_61_6096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptogenic organizing pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 271px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEPAVQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwfxj4n16HxZrMcWs6ika3koVRcuABvPHWq9vqPjW5jV7a58QTIw3Bo2lYEeuRWf43/wCRx1z/AK/Zv/QzXr/h3U7z/hHdKhdhJCtrAAuANoCDH/1/Xj8QDzB9R8ao2HufECkdi0opBqfjQ9LrX/8AvqWvXbcR3EpU8HeT06f5/wA9KsSWAVsnGR1OP09qAPGf7U8Z/wDP3r//AH1LR/avjP8A5+9e9fvy17A9phieADxk4GaFsCzYSN37cLn+VAHkQ1DxsxwLjxAT7GalN944HWfxEPqZq9ss9PKgBI3DDj7uME/Wros/Ix9pJC55jXk/Q+lAHgY1Lxr/AM/Ov/8AfUtSC88cngS+Iz/3+r3ARLcsY7WJo5CMExjLfie36VSubM2JJuZQzZOFiwx/E9B+vegDxz7b45/57eIv/I1SSTePox+8PiZe3zCYV6/HqMqf6gCPj7wGXP8AwLr69MVEpLsZJC5bOMsckn60AeQG98cg4M3iIEcdZqb/AGh42zj7R4gz9Zq9mCtJySFTPLEfyrQ0y3+zss0cTmb+8T/q/f0z79vU0AeG/avHeSN/iTI6j99Tln8esMq3iU/QTV70XAXD3CALztXkdP8AZ4/WsbUvEFrauYUmeRwdpbGcH060AePGfx6oyzeJQPcTUz7Z46yR5viPI5x++r04a9azzBjIxycZYcn0rTtrnzI94ZZIhyG6kZx+I+nfFAHkAuPHhGQ3iQgegmp6yfEBlZlHicqmNxCz4XOcZ+uDj6GvY2cEb4myB82P4h349fwx+lWLHUPLO1l3rxkZ+YD69/1oA8Xx8Q8geX4pyf8AYn/wpjv8QEBLjxOoHJJWcYr6OiuElt1HmFVzjkDIHrxVLUljFlIDLlTwB6D86APnj7b44P8Ay28RfnNUkdx49lIETeJXJ7KJjXsf2WLylmJYRk4x0Na2hvbreQrCJQVzklsj8fegDwwr8RR1i8VD/tnP/hTW/wCFhqcNH4pB90n/AMK+kLjUmRRsyqk8En7x9z/ntVWe5MrHLgKF5boPoKAPnfzPiBkDHifJ6DbPSGXx+Dg/8JNn/dnr6AkvkRNsOFH8Tg8t+P8An9aw7rXooJClvHvI/iY8A/1HrQB44r/EBvujxOfos9DP8QFGWHicD3WevV5/EF1J1kxz06UsHie6hf8AePG0Z6gj+VAHkhufHg6v4kH4TUhuvHYIBk8Rgnpnzua9wTVUnAKhGznIxyR9Ofz5qRmhugV5Rx/dP+R/KgDwg6h43GQbjxCD7mahb/xuzBVn8QlicAAzZNez3EZ3KJudvOR1x/n8KqSLsKll3A9Dg/MP8/56UAeRSah42jCmS48QKGztLGYZx1xTf7U8Z5/4+9e/77lr3S2v7doCl8hlzgM4AbzVHdlPBI6Z+9juO7Ta6NKuAjxE9j938+3b1+tAHh39p+ND0utf/wC+pact/wCN2A23HiE/QzV7/a+H47gl4FURgZaRo8j68EkD0yKupo0cRTzFM3PUHcOlAHzqt346bhZfEZ78edU8Z+IUufLTxQ+MfdSc/wBK+j4FCIPKjjAHPTnHrWtafaEZWjmIbphe4I5yO4xQB8xtYfE9bb7Q1j4xFuSB5pguduScAZxjrx9aydR1bxlpnl/2lea7Z+ZkJ9oeWPdjGcZxnGRn61+gHga9hm0xbCYKHjctGjemdw/EHJ+mD648A/bmUA+CiAAT9tycdf8Aj3oA8H0nxJrctszSaxqLEORk3L+g96KydE/49X/3z/IUUFIPG/8AyOOuf9fs3/oZr17w7GT4d0piP+XWHHOf4BXkPjf/AJHHXP8Ar9m/9DNe5eH7SVfCujSND8hsoCGHP/LNT+FBJFsMcokjbbIG4JPPFbum3aThoiXRujJnGR1HHfnmqX2MgBpQQf7q9QMcc/5/SprOBVvIjHGVO4AgtnrQBZvIzEjSJDF/eJZSxH+fpVVZb6Z1SG4k5Xd1CqB6k9MV2FlpkdzJjayksFDBuB68HrRqemadYSvEJJJcdcJxu+nH4DpQBzsdzdQZEUxeU8tNI36L7cdetIuuWqgCe0F4/QOWKAc+nf8AGkYLOinY21T1J681l31uDIHjwS69fUj/AOtQBrm4hv0CRXKxr2h2iNevXA4P8+tUX320hVwMZ+71H+en+eKy5wQu1eccj1qxZXzDEU6+bGCNueq47fh/jQBOLEXAZ4MAqM7BxVU2zCULKuCOAg43H/CugsreF4xNExMa8quPvH0+n+H1rP1e6haNklwVPV+hY+gNAFZZYlO4BJinG7ogPbHrj349qo3+tgPiR/MPU84A+grH1GeYxsYRvReg6YrmLm6HmOZGBbqQM8fnQB1Go+IWEICP5e7gAHpXDXd4yzv8+Tk8k5qnqN6d5xkg++azGlUkkgZx+VAGyl8CcDAHbB6VqWWrTwtmOXB9z/kVyXmJuwEHPOM1et7iNgBjYfUUAej6dronXZMpDdSePX8P8it+0uY5ZAzhSx5DKep9x/k15lbs3ylSjZyORntjp6+/Y4Nb2jXs0DKCRhRj/wDX7UAeq2U0SRBgwdXU7iTgg1ma1cBLUxsCec5Cg89qo6deGS2BjIYjggH+npUOpiWS0Xa5LFicbu9ACpd5VmJJUx4Ix7cfrWl4dndZtzKxXBxgYxx1z+dceI7k4DMSueFzj9a3NNUxlTvw+DwCfegDpru4XftAHypgk98An+f+eprPluMKxkY7sYABxznk/pio5p1jQEEyHAUk8fTH61TY7iWOSx5/X/P5UAQ6ncgQEsSAR64AHtXLXU6Ql2mJVM8AdTWlql8q5YfdB7VxWo3Qcu7nnsM55oAt3Gpq6ERbwAedzZNVotRdZAfkcd1buPSsB7gjJRR1/i5OKb9pkVj87D6cGgDvdK1k7QkgAPqBmteDUgW4c5B4IavM7e8lDqRKx57E4Irci1KZSMShmK87h070AelW12lxGASpcAex/A+tSyKoYjHykgNnj8T6HpyK4rSb+SV1EkWxSMhgSCfw7n6eldno93CgUBhMpUAOT8w49O4oAVNPmPRcRN/G4wR/n9R09tKCzggbJDSOBnLD5QfpVuNTKpZcPCeTuGMD/wDX/nrTVeK3Yoq+Y/VW4G4ZOfoaALMNxcCTbEXCqOMcY961rfU9PjUC9kMUxPW2+b8x0/z0rkb6SeVwHJVf+eY+UD8KZAm3qAOcgigD0I31rMym0tPtR6BzIATx/d4P5Zqc3t0Q32ZFjGPmjWPY4/DGa4mND8m7nHof19q63SZbiK2QyubiMjIV8sVH+yetAGpYatc28g8wCRcDKsOTwO/boOeteN/td3zX0XhB2kkdR9rxubdjPk5r3axt4tVCxuojnX7rY6+x/wA8V4L+1tYy2C+FI5kKnN3z2PEHQ9+tAHieif8AHq/++f5CijRP+PV/98/yFFBSDxv/AMjjrn/X7N/6Ga+oPBEMf/CGeH36MdPt8H0/dLz+dfL/AI3/AORx1z/r9m/9DNfVvgiP/iifDZOQv9m23OOv7tf8/wD6qCRt5po+Z4043FmUnj3I/IZqO1s4oMXMgV3/AIVPQn1Nb+0gLwcdcd/QVSkt1R34Cj7wzzn/APVQBZ0UHE9/cMrJCMLk8Bux+gFZuoXVnKpeDzHU5Jdxgk98f41b8TA21lb6fF1CpPPtP3mbouPYdRWFJlY1AHvj1oAhkKqCVCklfu/j1rIujvZtoIHTHr2z/WtQoGifJycdfUVlSJgYGc5x+NAFGWP1yD3p1vAXmxggHlu2KV9xYgcZHrVq2Rtu5yVBySe4H+f5+1ACz3bW9uACFiUdB0Ue3vXL6nqiXMgVcF8425+7TPFOs/PhWCRLwoHJP+eefrXB32pO7FYyUGckdz9TQB0d3qHlhgX5zgIvzZ+p6ViXN3bzE5jCODnPU1lHUHVSmTsY9B0phJfOeMd/WgBl9HJkvHIjAn2zWZI0q8MSKvTZILbxjvgVXc4JBbPGelAECyPz82frU0U2CNw/HFLEI2fEnQdeKnS3hVt0crI4wuRz1BB/SgC5a3qxgjd1HH9Oa6HTrhZSAXAXuw5x9a5dLaMD5pQDtyQy9609OKR4PmFhnlVGP1oA77R5SuGidcepOORWpeBJGCxE7O46c1yeiv8AMrRMzbTyD0/z71utcg+UoB3E5OT/AJ4oAfcYDhF4jXgZPp1z75rR0oI8n7wYXHzFe3asZ7hDvC885+lamkyKPmJwoBB/KgDWl8tQhXOfmwvXAHFZWp3Ahick9BjK9zV+5d3VGCHCgkbvXH/66wNWVpeA2Gwd3HT/ADg0AcjqlzLcsVHC4OFH+PesC4bJZMHOeDjp7f5966yWwkLjdLGnPQ5J78ViXNtFDI5DO5ycn1/yaAOekJXseeeRUe2R2wiO3pxV6XhshNw67ic0zziT88nA6gUAPtLSQunmlUBPqM1sQKkBG1Q3qc5rJt5V3Ak8rz9atI7FvvK3+ypxQBrRXLGUZYnJx16VqWl15CiTeev3t3PX/wDXXMm8248wEgDlcZz1704XQmK4OG9ByOev9aAPUdE8TLOqQ3Emzdx5o6n6/nmujSIGXITy2Y9OxOMZHv7V43aSuCpHIJznP869E8K6yZoRb3LlmXhGJ5+maANqRPMV+cEA5Vux9Kjhyr47n15/OtO7iziVcDIAfHHbg1UgjCzLvBZQwyu7G7nJGe1AGhZkn73QDsefeuq0kIyovTPAGPyzXO26IJXEO7y2b5Fk5YDsCf61uafujnUDGM4x/UigDutDUxhdjgMwxz3P1rw39trPkeB9ylWH24cjr/x717PpxBVRnJ68nIH+cV4T+2RNJIPCKSPuCG8C57D9x/hQB4Non/Hq/wDvn+Qoo0T/AI9X/wB8/wAhRQUg8b/8jjrn/X7N/wChmvq/wOR/whfhsk5H9l2xGcj/AJZqD+HX8vevlDxv/wAjjrn/AF+zf+hmvqPwRK8fgzw+VbaF0+2I7nPlLQSdjNbsUUooPzEsOnXv/wDWqO0tGu72ESZ8tDvkY/wgc8/XH86uaReRTOkUsY3t93rnvxnsKnu5SI2it0CRHhscZOeSfWgDk/EQee+mmf8AjbPHp2rGkOY8ZUHOMHmut1RROCCAAf4RXM3UWzIOAc560AZ0jcEKVAI/CqMq9uhzxx1rRkRm4Ax3qIRF3zknryPX/PPNAFGG0DttYFUHLn0Hp+OMfnVbxHeJY2jlgN7DhAc7V6/4/nW9Lss4WcgZQ5x6t/gPSvL/ABVeNcCRmfhnBz6daAOV1S5aad3csXJHPp6Y9qwpgVfLH8B1q7eSDLBMgjqT1H1NZE86INoUOwJye1ACtJuG1Rx2x71EZjG2C2DjB+tVpJmfO4/gOKiPJoAui5QMAQ3v704TRyED19eKojHO4kcdhSUAXgwB55yOMU9HHUMMD1qgjlTwakMgcjdwfagDVS5/hGeOnatPTmWV1zjBPXOPyFc0hIGfyxWjYSssgOTwR07UAd7pS+REjKCJJMk46bc962JXchG2gr0JxiuZ067LNu4yuAvGR1rp7nMka5yOBx0yaAHwRxvuPlrzycHnNa2nNtyI1QHGeD/ntms6xXMLZzke2RWhpyl5hk5IBOQOnpQBoGIhmDE8EKfr/k/zrG1cgPkN8p+72z2/+tW9NvFrtznJyfU/X9K5PWpCZ5YeWjc5A9PTH4fyoA5m8u8fMThTxn1wB/iPzrGuroLgxjv/ABHOP881pXdufMOI8FiFwep9KyLsoCc9v8/nQBQkZnYhySxOcCoOnLYUY6mklkbf8m2IdM8/zqsVUnLkkH07/wCFAFgXKhfkznPFRmdnZiAfU47VWcgZwcA+npTTwqkk5oAsR3DKchiOfWrdvdHePMGSOcjgisyPlgU5YY4IqRSQeeAccn+dAHV2VwHx5bdB909RXT6NKGbcpKOCG3HjB9687t5OVZWwQcjHaus0DUNsmLj0A3Dt9aAPatGuPtVkoOC6/Kynv7flzVloBvUKBhvu8dvU+4rlvCt55cmwnCPgAg8exBrvIYTIhUjBzuGR0Pf86AKtuhWXacZB454P0Pet6yXgcc4rLEZVgcDA9R/nFbFmvCkg5HOMY5oA3NOJ+U8A54H9R614h+2EMR+EOMEm8+n/ACwr3TTgV2r6nOeMmvC/2wRiLwfkYP8Apf8AKDigDwrRP+PV/wDfP8hRRon/AB6v/vn+QooKQeN/+Rx1z/r9m/8AQzX1H4MVpPBXh7ywc/2dbfN6Hy1r5c8b/wDI465/1+zf+hmvqvwVJJ/wg3hxcAJ/Z1typH/PNff9OO9BJsxf6LBLIxPnYZQP7pIIzz3/AJVa065Z7QK7ZaM7ctyPzrNlYeUiR5xuznp24HP1zTLNvLmYjqR3J/z/AJ/GgDQvvl3byVGOMj/OKw7s9T69Oetat45K/dIPfHHPvisucMPmxj3HOT/OgChIwABOF9/T8KLUAvkgFl5xgdT0/wAfwpk3QKScdTmpo0IjOOigk+mSQB/9b/JABieJZwtoAWBU5RefvAdcd+uOfpXlfiS6XkSH5EHAXOT9Py9s5+tdx4yv0Rjk5jT5VQfxEdenufrxXk2qzvdTO7EckkkdBQBlXlwWJHAjB4UHg/UjrWa5J6Y6YzVufahbkE9ie/0qox+Y+aCQR0Bxzjj9aAIj19aSiigAooooAUHBzTsg9aZSg+1AFqKM4+X8c9qv28b7sbVH1qhby4PBwRWlZyYIxjk8ZoA6XQbWeKLzvLdod5RXx+734B2k92wQdo5xzXUJIzvsYkbRj0BrndIfejKTJ2cIr4VT0Yle5IwAQQeOp6DorYlJInPAZtoz3FAGvYHESL2YnIHX0q7pAJZto4xjjr9agtEi5HlgrnBx0x7VtWK5gxGqAMeffue9ADHQtHkhBnvken+f5VgazZbmEik4P3sgjn1zXXTwOVfcSiK2BlScdh+ffp/IVk6oim2XJAbJ78+vP+R+dAHn+p27MdrRkjBIOPzrltXdopf3agZP1/8Ar16BfW64IU8nODxxXBeIxMJnUqqFTg7e47UAc5cyAk7iSR1xUDNtYZz06E0koyf1piBSW3nHHH1oAC/GO2c9aQnPsKQ9aDQAq9c8fjU245Bx29etQVInBznGKAL1uRtXqCPStiw3xg55QADg1h28q7gZRlfbg1tafKTgocp3HU49xQB3Xhi/MTosnzR55A4Ney6DN9ps4cOCwHyn+VeFaMCfmRjuH8Oe3rXqHgbUPKdIpW2xMcDdztbtQB22zkAdCSw/H9K0LKMKOvzKcden/wCqgoAFYBt6tggc4JFWIFETZA4OOMf54oA1bEkFQM7/AEzyMfzrwv8AbEx5fg8j1vM85/54V73YAmNODgY7A9RmvBf2xceR4NxnH+mdR/1woA8H0T/j1f8A3z/IUUaJ/wAer/75/kKKCkHjf/kcdc/6/Zv/AEM19UeDOPA/h7OB/wAS22/H90tfK/jf/kcdc/6/Zv8A0M19OeErjb4K8PqP+gfbjr/0yXj/AD70Emy8gDsAw+U46nPOeM/5/lUQfZNubBAJHXpn/Paq7zEODkZGeR+NM3EuSTyMYyP60AajyBsAgdOnYj+VVZnyxwcH2P8AnNMjcuu0Abvfgfqf51HK5JY5HJ9x+JoArld2cHJPC47/AEzUt+62dq+4/ImWfB6Y7fWpbRCZlcjiMbj3yew96xfGlx5VtFEWGXG58cZ/zwaAPNPEry3EX2mZG8pm8sMOgbqFz24598E9jXCXzFydpUJ2PYe1df4jZNqyMR7A/wAXtXB6hKXPAAQcAAdKAKU0g5CnJGOaqkkkknr1p7NnP+cUygAIIJBGCOMUlFFABRRRQAUUUuSaAJYRlhV+2Vtw69ahtId3HByK3LOyLbXAJzgH1zQBs6O5jU8jzdpbGc4568V09gvmSxySFiGIYelYVkk8dotsxYW7SedsIH3toXdn6ACuh0zeWjjwMHgcdaAN21jRo8k/Nn1/nW9p0SmAEjvxwPwrFto8INwGM4we/tW7p52qV9DnoT0//V/nuAWZ1/dAtkIO3+fr+tY2oruTC8DOf8/p+lb0inaATjP4/nVOS0zG+RgjnJ60AcjcW/BAjG0DOD0Fcn4lsRJZSOFDbeeh5H8+v8zXolzabUwQVPQe/wBD0/GsTVI12yx4HIK7v5fhQB4ddxFJWwMgHAPSqZGDg1saopEr4zgHAPY/jWRjoKAEAyeKSlBwQRjj1FHJ5P50AL346UobHJ5x0qS5kje5ka2SSKAsdiySb2Vc8BmAAJAxyAOnQUwnJyfrk0APiI3A4GO9aensRMhjyrDGCpxz2rOjVWyVGB7960rNzCCxC5xwCKAOx0edXZYwAkrdRwN/09DXe6AxYbE4YD8//r15bpszbhghQD2Fd5oN80pjL4Mo6EnG7/69AHuekzC8sIWYZLp5b47npn6irSIzAZ+9nDDA65rA8HXIlhVfl55KjuOma6rb8/zY5ypxzyP8/pQBp6WR5QAAK9jjr1/rXg37ZO3y/B20/wDP5npx/qOOK9105SrbSOQe54PsP0rwv9snHl+DcdP9Mx9MQUAeCaJ/x6v/AL5/kKKNE/49X/3z/IUUFIPG/wDyOOuf9fs3/oZr6I8LMw8H6CAVz9hgI4z/AMs1xXzv43/5HHXP+v2b/wBDNfQHhcj/AIRLRcAn/QYPw/drQSbgcMwxjGeM881KrYO7nPYgf596oI4STA6f1qxG+cjJGfrQBZRgGIPfnH9aNxLkgDC1AxOADg/xcDn6ZqSMMCgzySOepBoAv2iZH3QQELN6gngD8v51wvjS7DXTuzHYpIUA9/pXoEsqQW+ZR8uC8mOBgdB/KvGvFl69wzMMA5yB6DvQBx+vXDTyE8YHTBHfH/6vwrlrrH+INbeoOFACgM3cnt9KxLgAEmQn6etAGe1Np7nLHAwPSmUAFFL2pKACiiigBaSil7ZoA1dKUOBggnpiux06BUKhhgcEGuK0QF7tEGeW7da7Qb7ZQSevygE9PcUAdBbHdL8o/d9sV0em20RZG2gDOMkA1ymjSqqAN82GBK9Bj613OkSebcIuAEAOB0oA1Vs1jQqSChIJ45PerViigxKmDIeAccmrF1EViJOQNo6jtiq1s3luCu75R04H+f8A69AGz8rRZTChyASOPbp+lVJkHlkFc5+9jkd/14P6VLFcbwquq4ODnplv8/0qG6kxG3ljkjJzxj2H5Dn3oAx74xoF3EKvP4f/AFq5zUmAclUYkHkHp71v3wdsuQS3ckYzWFdxfN90kZIOe4oA8V1xWE0oc/KGJB9s1gnrXZ+JIRCbhCq7kJ5I5FcYcYoAByaCMGlTJcY60rLj73X0oAbngcY/rS54HApP1oPBODketAFiHaMEEdeFNacDIQVYE57Vjx5J6dK0rE4Yhl3L69xQB0WmQ/ImCTu/hzyBXT2biN9kYIC+pya56wKBS1sSe2f7vsR3re08JIQFdd+7JOMDHp7n3oA9a8E3ZaWIu/zYG9R3z/SvSwMjJ5JXd07j/wCtXifhS7ME6MgO4EDGeo9K9s051nsldWJUEMpx2PagC3aDDJuK46+uB/nkV4T+2UwMfg4DoDed/wDrhXvNuCQeRkc5NeA/thkGPweAcgfbB9P9RQB4Ton/AB6v/vn+Qoo0T/j1f/fP8hRQUg8b/wDI465/1+zf+hmvfPDBP/CLaJzgfYYMHPfy1/xrwPxv/wAjjrn/AF+zf+hmvefDR/4pPRwRk/YYeo4/1S0EmmeD8p5wcc1OnytwcfWs9l+divuR6+nSpYdolDSKWXklQcfkT+BoAvKxkcEljtPAxWpYxj7RuY8RpuyR1J4xVCzRtoJPBJIz0+vtW1p8YWAu3Bk+diOyjp+BoAyPGFw0NiIIwfMfC49s5wa8q8QjgqpyxOck4yMd/avQfGF0ouDETljyxPbPavNfEc/7pkidd+eeeQPT6/8A16AON1WVYJtqnfIMHpwKwp3bduclifWtG95Lbick5J6+9Zbg5wCTQBAx/H3ptOOKRiCeBigBKKKKACnA4/Him0tAChc9SAKkhUMcHPIqJcZ5OKkiwG4P9KANfQR5WoRODnaT047V17Rmdt+05zx2/CuU0ZD9sVjggc4zxXoFjCskaJIrZHG3pjBoAsaNblQMrurudJhMe2RR8wxj64rG0OyEzqsecZzXZwWPlxxxpyqhR9fegDQZN1sCN209vrVPyNjcnIJHv9D/APWrZitwbXqeAG5GMD39qEtRL8jFsHgD3/zmgDMZMIhVRx0+vqafNEJEJI/hIxjgH/CtN7HbH8w55B9T/n/GmxQKqOCwOT6ds/8A1/0oAwJ7XcuF6Ak4x2/yf1rGvLBmJ24XHGSR+n+e9drNCNvPbk9uPb86xdXtgYJSOWA4GOo/GgDyDxvo3n2kk0T/ADggMAOo9a8oliKMwIIIOK+gNagja3O4pjOGHNeU6zpSQ3roHAUncuR1H+NAHNWkOZSSDgcD61FOBv4PtitKVI41AEnOcYweKz51XJCsD14oAjUE8Dp60hQrnPbtVmNUXLZJGATntUZXOT14zzQA2NCTnkYq/A6hht4bt9agjRmxjk59avW9tjO3g+/r/SgDRsXkilV0G2QcAiun0+VHVc4EoGTHjqPUf4Vy8HyS4bB7/erWtJdsqOGwwOVPcf59KAPR/Dsm8jqJQcoT/F7V7N4IuQ9g8S4ZkwwBHr2/A14foM6zQoVC+YOXUd/evWPBVy0dyX3fJImGX1/+vjP5UAd1t2S4bGRggkdsV8+ftfsSvhEHHBvOB2/1NfQMi7fKYjLDMZ5z9P8AP0r59/a+Hy+Ej2/0sAf9+P8AP4UAeG6J/wAer/75/kKKNE/49X/3z/IUUFIPG/8AyOOuf9fs3/oZr3Pwyx/4RnRdvUWUII+sYrwzxv8A8jjrn/X7N/6Ga9u8Nn/im9HIzxZQdO/7scf5+lBJs7Qx45xyeep9Px61JbpmXaRn8cYqtE3JKkg9MjtWjYjc44zntjqP8KANKBW2qi8FhjIPUf4VsKALdyOU3bRkdgKo2uNxODlVyPr0/OptYcWtgyEnciDJC9270AeaeKb5nu7iXq7k7RxwP8K8/wBW2kb2/wBZu5OeK6nxDMZZw2WXcMKAPyH/AOqubumgtlP2mPe56IPuj/GgDnbpQ+RgRx/rkd6xZ9oABz784rY1A7y7pwnfnj8/89KypmTcTGpwSeX6g+n+fWgCk6kHOMA+tNOOMU9wc5Yg++aYRQAn6UlLSUAFFFPjQv7Ad6AJIIjLheg9alNsVlVcHBPpSRsyEAfpWnaAXTAOvUjJAHA/z2oAsaVHsywJIwBXf6IzSou9mc9CW6/j61yENuItobB9hXbeHIt8kBGFxwTgn6fSgDt/C8JEwxtZsYAJ4z9a61Y0zHtYkqDnHOT7VjaVafMoRSu059Oa6a3ttkIZsnnPzHn6mgDQ0/5rVg/GGPYHtzSQ4jaM7mJBx0xjnvmrNnEogdmUZB9OM+lRpCXfABy3GM8n+lADpbVXRERwOeDnBH1z06Vnzx7AxJbqw2nqPbH+elbCQsIA2BuJIyDjjvyPr+pqvcWyyk7uoBI4wMZ/z0oAwTOBjaABzls5xz+v/wBes7Vo5JbZ2Jznvz+X5VrzWjIpHIcY6++ef/risq7jZdyAkMD6Z/z/AJ+lAHLajp7NaSuAcDDYPVa8x8T2KqDKAcg9MdPevaTGZImWT7u4Ak84/wDr1yXirQVtnchRJE3Oc5xQB4heY/uBT3OMiqMiRNyikZPQnOPxre8R2jQ3jqEyoOcj0rEQN8uIztHJ+YLkD0JoArBXJ27SB9KRcr97OD29vSrXmNsOTyRjilWNT0Hbk9PpQBHE4UAbevcVbgTzQxVsjvjqBUPlbRkMcfSprdCW+VyuOjDtQBoWyFgM7cDgZOPyNadsqqWZmynXPQiq9o0cqF59qkfx4wD9QP6Veto2SQKNwx2xxjtigDrdClMPlSLgMOx6GvWvB8ytcxSjJiYgDHWvHdPTy41YtweSFFemeC5sCHeQsTnoexA6+1AHsOw7I0PO75M9ckdM/pXz3+2AAIvCAGRzeZyef+WFfRNt++tUkYAlGBIz07Z/DFfPP7Yy7F8IKOmb3Ht/qOKAPB9E/wCPV/8AfP8AIUUaJ/x6v/vn+QooKQeN/wDkcdc/6/Zv/QzXtvhrP/CM6T6/Y4cf98LXiXjf/kcdc/6/Zv8A0M17X4bOPDWkZ6fY4fUf8s1z9e9BJqo258EAjOeT09617ALtXBGT6/56Vjxj5hk4Ge4OOv61uWgOBgZ3dQKANvT0BycjHoM88ZrG8c3RjhWEHmdjJ+A4H51v6ejNDHtzmRyxxx9OPpXFeNpjJrEzL0X5EA7YHNAHDauxiV2KsZO2BzXGX0+0Avlic8K3P8/1+lddqwTyt0g3Lg4Uc9e9cJqHMzbj15wOe1AGXdStKxYkDHbHAqkzFT94gHsauXB+T5cDvVF1yM85yeTQAw//AK6QnPbmg5Box6g0AByeTSAZpynacilG3ucCgB1v8sgbLBlOQR1FXLd442AdAxPvyM1AdqRrgFie9T2hEsiBlGRxlvSgCxHB5hJUAA9TmtWxtGRTuB6g8nH8/wDOataUEEEieUiEkjJQcn/P+elWbiQC3CqobHy9MAen9aAJ9JtDcXPTarZLHPXH+f1ru/DcADDYD5SEAZ4yfrXM+FLSOZizh1RcHIBx+H6dP/r16xoGnQeWpZWLEAsG7igDX0O33j5RsXsAPeumVWRFyrBl4xtBH5Hj8TVWwtRExAYgrzyDg/Xp09uK0thdo2jwTjjrk0ASRxMsBAJJ28E88fjRHEAVBAGRgDPUfj+ff/C2ik8b8BTjDfShI5XA3bDuORkkY59aAHKuV+8w789u/f8AP8KR4FKs23bxxjnH4den51cA2ocMAqjsO3rnpUiJknCHgHHHJ7gj26D8/SgDAntFMYyMbTwSSTzmsS+txCxV4gdvYtycda7C5VE++fl7rn2/LnP+cVl37RlSpWMkcbm5/wA/jQBgRW9u2WUFHICque1ZWtac0sBQJvxnHqeelbdjI63EoMibWHzBgAfwz3qxJOjs+yKMhR1K7Q319/egDxDxXoUUkJPk5mGQgUjIP+FeWajb3EbOGtyqoeVJJ5/Lp0r6J8UowcubXco5UqxXFeaeKrC3vYpWKGK6TgngjjqCc8/WgDynaxOcAY4xUkKOVcKF98GtCWMAmOQhSOMHIwfx+tMjtvk4IXPUnkGgCrGOgbaPYnvV6G1OzcpXDHDD1/GoHttgzyRgdRjt/jmrFtH5bbhuYH+Hrj/PvQBIiLk8sw7ZGOa1rCWBCFmdnXPKjt7is1IXWTKrz2U9/Wr9tbvIinaQoHUjAA/r9aAOv06JkWNotrqejBuT+Vd/4dBjXaR9084JwGx145//AFcV55oEfkkeZl4uPlH8J9vavSNE8uNYy6FwxOGyDkUAex+FZzPpoduWUgOMH8D+Wa8C/bPQRyeEVHb7Xjjti3r3LwOcb4xzHIg29/mBz/n614n+2qPk8Fk/exeAn2/cf4mgD580T/j1f/fP8hRRon/Hq/8Avn+QooKQeN/+Rx1z/r9m/wDQzXtPhn/kWdIOAP8AQ4R6Z+VT/T9K8W8b/wDI465/1+zf+hmvavDIJ8NaSPWzh9/4F/z70EmvZgsw/Qg5JroLSLKYUDPGD9e9ZenQlpdzZHGAQM5NdTp0OJY/UHPQHP19aANDTosmQgELGD0FebeK236ldPJwpJz6Y6fjXrEFuy6fLg/vZcNtOeAK8n8VFFvHCqH6knquaAOF1ZWuHO5e3TPX2rl9UtnEnEZJAxyOT+ddpcxsTLuXYCM5xjbz2x1NYuqWQVQUG7B5BPJ/+tQBxE0DByChx271VkjA+6v+Nbd1bPFKGX5NpyGz0x6fiP1rMmGD8mNv97ufr6UAUmG3J3KB6AZqN8DhQD+v/wBarBUjDAgY7n6Y/LFRvCynLKR7HrQBD5bE4wc9eaFQk4II+oqZYTyQBnsKt2tvP5jCMlQylDhsfKeoNAEUKecQq9a2tK0gOrlnAVQPmI461NZ2iQJmRc/pXUaQiXFsIFTAZ/lA6ntn2oAyZFgtYcR5YDneD1znp+HermhpHfNJ9o2hVxtXGAT3/r/9em3sSx3kkLjaIzggHBP0/wA9qLFRG5BOwPhUIH6/0oA7LQoYoIgspxuPACg8e9eg6PdL5SI4wccsBww7H26CuW8P2SS2cBUPhVwT1/z2rsLCy/dBWDbyflZff2oA6OzDSzeqbM8d61bZd3zFcDgbe9Ms7VoUKlQFbp1/T0rQjgKwohBbceD/ADoAltBtUM2N5J4J7VJGVUA/NhenbgH0oUBUOAMf561JCucAfmPWgCZ0BtiQp3NyRTiFbcMYAH1OPTj61OsYMO1hz1yalFuRlSoxzgnv/X2oAxpoxtwAPm7Y/E1m3cLYY+jBcnPP9eldDJDxtKhsnBIJwTycj86gnjUKgKAsck8nnng0AcZcWZSZ32kYOAg7f561WtdyPuAGGOFyc/XFdw1vHNwqYdgfX5h7VRGnxLNkqDt4HJye2PY0AcnqWnLcwHfHuyu3GOT7f15rzzXdHjt3O/lQegGf19Ole13MaLEEaP5c7Bxg/wD165jVtJ+1Ixym04ycc/X60AfO3irw6XzJaIrbQCcDr+A/pXFNHNCdo3Lg4x/iK9+v9CmhdE2vIhxg5/OuH8QeHmaSQlAH5Ppk5PH+fWgDiYr7OxrlNw2hcgD8iK1DHbS/Kj7QoAyhwfy7VSTTJGuMRqSecg8A/X9KRYJISxZDHJv/AM80AbKptjARy4PzDAqe3UOynexkJBAAwaj0ibMu2TCtjCv6Z9q37fTwBuiA3E8jOQT7UAJp2EYKqlVHvmu28PTEKsTALGeQy5+U+v0rCg04Ntkb5ZMc4/r/APWrpNAtiVXEbMBwcjnFAHrPgTdvCn5SCAPY/wCTXjf7bigHwZjv9tP/AKIP9a9m8GgCJMgq4PHrj3/z6V4/+3IP+RJPc/bc/wDkCgD5y0T/AI9X/wB8/wAhRRon/Hq/++f5CigpB43/AORx1z/r9m/9DNe9+EbTd4X0Ug/esofwPlj/ABH614J43/5HHXP+v2b/ANDNfTXgm0ZvB2gMoOP7PtyT/wBs1oJNDSrItyw6npjrXT2NmzTImRlvlHHI561Fo9m3Aw3UnrXS6dbYmDAYYKevY9P8aAKuqbbfT7iRcDAKLjseleKeI13ygqwCqecHOQa9q8XJ5ekQL0DybyT9OuK8k1e2JkYA43cKOtAHKOpYbEjB9F6nH+NYeoRpG2GX96AQOeB9T347V1F2XgUqWUKQdzrgH6CsaURAtukII/g7YoA4u/ty0hx824ggkYx/n/CsqaylAIHzbucAZxiu6uIoZMhn2behHzBPcisy6s7gFy6HnJLKm0cnOP5/pQByBtyp5jc+vpTmhZjuVflHoeDXTQ2UrBxlkDcnPNSCxt4xmeZuW6IM/wAulAHPLYHGDHhhySKt2discSkIzu3bv9K1hZSTviMsg6AEgAUl6jW7bANuMAHufpQBo+VbwWwaVVkRVAbpkE+/6cVNaTK+TAoG0Aqc8Y45NYfmJv8AnDsCuCvG0D/HPNadpNPOFEVvFGTtBZV+bgYyfcgD8qAGTRPM8hcIw3feIPHfP0rW8OadJeXMbvFtUYCgj7qg+n+ela+j6NcNdwSMpMYxhB/EOvPt/Su80zTRbSBIlCp2YjJx0oAXQbAoWAA2cYHTJ9v8a7HTrQEgkYKsMegqva28hljUruCYAIHI+lddYQKQrY+XGcen1oAntrb90AEkz03YABqTCqu17dix/n3PtV+KItEhUlcdfXNJcxyF0CBjzyQeF+tAGZIycfIVHXI61PCyjH38+w6dqdP5ib33DHqKfZF2ZfnKjocgHmgC9GihG5OTnt/ntU6ISSHPOMjnk/Sli3eQN2RjkAeueuatxoBxwOPTp64oAz2hJx8oBPr6VDPDkMD97PPatbbjIIPXPX6/yqKVRgjBx060AZAgxtYIePX+f/1qdJarJKzsuAcdBjFaUQOQMoE3Y49RRDu8x1dOM5oA5q8sTMm35g2cYPf3rFurCSKVirhlHDArgfX0712k8ceScnPOcc1nSQtID5cgZSSDzzxQBwmpaPuXfGrDqcjkgden5/nXJavpDyxsZI1ZyxUv3Bz3r12WFhEVVSHHPI61kXdgk8LJKgZdoVtvUfjQB4NqujK0o89WjYgD93xzWFLpkkEmyUK6LkAkYAPIJr2vU/D8LggS4QgbQwz68Z/Kuev9DUTbbqLCnhSeMkUAeX22jbZlMOQuOc9fXrV+BmikJTIQHHToPWt2+0prRWaAHk8Ef0qGC2ZpAXU5HDk9DQBpadvuolYgOikj5hhua6TTEYALldyjGFbArL0uBxMSo2YwAoHTn0rtbCyhu9kiLtYdeMe3T160AdH4MYxygnkH73Hb6+vI/OvI/wBuT7vgj/t+/wDbevcfDtltBKg5B+Y+v+NeGftwgiLwOCckC9HXP/PvQB856J/x6v8A75/kKKNE/wCPV/8AfP8AIUUFIPG//I465/1+zf8AoZr638A22fA3hx9uf+Jbbc46fuVP+frXyR43/wCRx1z/AK/Zv/QzX2d8PIC3gDwwcAn+ybXHH/TJetBJv6dZ7YwCBxwffg1u2tvw20/fO0DpnH/1zTLC22r0BwM5A5PtWzaQEeWepznnue1AHI+O4t9rFEvRTuIH5V5prEBXfhgjkfO+M4PoPevUvF7Bd7fN935eT68//WrzjVUU5UP93+Jl5H4f5NAHA6pp7I5cYYDoFbPBrn54g+4EEgc8jvXaX1pl2IAAHOACNxNUF0WWQNKQFBP3c849z2oA5N7QvKHCHIyTkdTTLeBbdADJM5z0I3fp+NdeNOiXdHOykFcAKN/PTnHSoH0x4NjspRSpIIHLfh24zQBzUsfmlleAANgAr1xxUI00HnAijIyxP3jj+VdPLukOLWJADjcxUlvXHpjr71De2kklkbdmcysd3CnoPUfrQBy1y/k7IYFxhfmHXj2qtcWzFfPkOZCOQGzuH+Fa50sxIAVPzfxE9f8ACtXSdHVmAKNs+6x6gd+P/rUAcpp+n/aJd2FfacYHBU16D4Y0OFDEzcmP053f/rNS6dpsEDbLe33NnJwOp7Ek12OkKAgijt1SVgMsBkA464/SgAsdOD3+078KPlPP0/ljrXU2OmptcPjA4BPTsBj88VbsrGTY0zJgnAwBkA8YB9T1x9Kla2cMwRe3Azn06n8P884ALVhYoJFKMXA4A9/b1roYtjbQi4HUjvnArGsIGWUA5AJ6+h45rehi2yDdyTj/APVQBct8BckHOaZKgzkHnufSrSoS44JYA9ajnQqmcYNAGPd5MeRjOeB3FNskO5T1JHJ69+MVbMRkBIxjqOQB+fap7S3ZMZAIPQrzQBbVSYgCBwcZHp6VOi7RzzxyOvrSov7scHkdfSpFQ5PGPp/n6UADL0xjNMKcnAz9am5pG6UAVRGCxU56dT3oKgquMZyD6/hUu0M3BHX1pzLk4Xj8KAM64hyxPfGOlUzborOGBwBkjH6VtzgDBJ6eveqssJcAAYOOucYoAzTFuVk6g9Q3PaqMsAWPeiFXHr0P+ef0rWMZVPkGMAfN6/55qAqSifd3cbW9T/jQBzc1oCAJI22jJx396y7zTFe3kQgtECc+oz6V0txEkj/LJtYAZK8j/IPBHsaja2jJIlzv6KUoA8+n0pWRwrfJtwFKg59KxptISOYNnJ5+VmzXo11axsSYwD0FZd3psdw52RsZMnkdj/hQBzlnZqylCuGHIweg+tddpdkUACHJ6ncMkn3HfioofD80cRZkYqQOmASe2P8APNb+j2nkumwAOQQ+7JH0+v1oA3NJjxGrqmxTjKY6H+tfOn7cowvgj/t+/wDbevpmwTZwckHHGOn4/rXzP+3P/wAyT/2/f+29AHzhon/Hq/8Avn+Qoo0T/j1f/fP8hRQUg8b/API465/1+zf+hmvuP4aQKfhz4S2rydKtO/8A0yT/APX+NfDnjf8A5HHXP+v2b/0M196fC2LPw38IEZBOkWn/AKJT/Ggk6q2t8xcAADjj2FaSxqijK8on41HaqCFPB9COcj61Ldtst5G6nFAHE61GLi4ZmDAMCOhbiuMvdPZZGRAMf3Wzx7mu9vydwHzAnk4Oc+9Y13AZSoRshm5xgD8qAOJXSLYZe5b991AB4PH8PNRSaI8km5i0US9N64H+e3vXpOnaHFFCS8Q3MM/Nxk/SrY0OIuWmYM56pgH/AD/+qgDzC08ImFyYQZGK8Egjj2H+fwraOgpwqoS4AHz4Pvj3/wD1V6GlgqDcBgE8DP8An3py6ckrq2Thc9OgGemOnrQB5wNAknQiRMpnJKLj/PX8aWfwwqyMo6Z7Yr0S5tgGP7vJxnr09f8AP/6qgFhuO9kLseB+VAHnNx4XjbdiBWfON23dnioW8OxCHyGfacFmwv3iO1enf2YRkfMD6A9qfHpCR4O0YJzz3/KgDy6Hw9NuzErsCcZ/wrf0bQDbRgybQzZGE/TP+R+FdymnZIATao4xjipWsUU8qpHTrwB/OgDNjj3RcpgFR8oXHsenf/OKnks0icLuR8jJIGec9vX8KtyxsEcKm0DGABjH+fWn26ttwxG1fl69RmgCjHaKZgeQx4PPb2/KtBLc8qASn161PFzIxzkdCc9f84qZY8fdzwc5NADoVKhQz5OPXPNV73PyqJDgnrmrBO1+eewAqKVN5JPX+dAFZYDgAPjIIxT4VYMP3pPHOfSpkjVcdMA8e1LGvTAOMYzigCzHyg5z29afio1DKuepqQUAFFFFABikwKWigBrgEc1CV+fk+3Axn/GpzjnNRuN3T6/WgCrIgBztOc9Pb/P+etRywxXClScNj7wqzKB5e0gkt6HkVXWFVT+6wXHv/wDX/wA4oAzJ7fIyVwMD2JwOuO9VRbB3ILDP3uvFbkYdwFOAcdR0P41GltI5LoqqHwcMCMD6cY/z0oAxnhR8MIjuHXH+eac1qkmTIjAdAw4P4its2HmdWDdzuFPk04O27zPbG0AYoAyYrfy3fcGzxhT3zSWiksFxliTkDg1q/YZVG1ZAy5yc8E/jUaxlGVZYhjqMDv6H/wCtQBbtFwi5JJzwRXzB+3P/AMyT/wBv3/tvX1BAGLbWYEjrnqD/ACr5f/bn/wCZJ/7fv/begD5w0T/j1f8A3z/IUUaJ/wAer/75/kKKCkHjf/kcdc/6/Zv/AEM19+/CyMH4aeDy2MHR7M4P/XBK+AvG/wDyOOuf9fs3/oZr9AvhUP8Ai2Xg49jo1mOn/TBKCTsYlPP1wah1CTbA2Dgnjj61ZQcD86pX5wpJGe1AGDcWgl3Aj5u3Uf8A6jWha6eIQjFE80cYxn+VW9PtDGokmwHPO09q0AgzQBmyxM8gz1xycVJHa7Tx07j/AD/nmr4UAY7U7FAFVbbPUAep9amSIJkqOT3qSigCHyFz2/Ln/PT8qVYEU9M1LRQAzy1wRjg80eWuMAYp9FAEYj7scn3oMYOCRz6ZqSigCFowCc8A8ZFMNsoYlSR9Ks0UAUwHD9AR6VKpLcYFTEU0qdpxgtQAxm3SbQeAOlIVGBnoOnNPSPHJyfY08r6UAVipA4459KdGoCj2HQmptgxjpQg2gUAGDtIzzTdxVsEHBOOO1SU113AigB1FIOnPWloAKKKKAIZcrIjDO3nOPp3puxt3yjA7+9WKQkCgCNkdtvOMdfWlSJFbgc+9PBz0paAI8EdCR+FOxnIJpwFFADNuDnNLjr6elOooAbtxyOKCuTk9RTqKAECjIOBmvlb9uf8A5kn/ALfv/bevqqvlX9uf/mSf+37/ANt6APnDRP8Aj1f/AHz/ACFFGif8er/75/kKKCkHjf8A5HHXP+v2b/0M1+gfwo5+F/g/GM/2PZ4/78pX5+eN/wDkcdc/6/Zv/QzX6A/CM5+GXg/dkAaRaY/78pQSdsvTge3NQrCGlDMMqvQEd/Wpo87efWnUAIB0paKKAAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU3BLZIxjpTqKACiiigApNozmlooAKCKKKACiiigAooooAY77emDUQuMgcZB647VL5YwR2NIsWAB6UALEPlzgU+gDAwOlFABRRRQAUUUUAFFFFABXyr+3P/AMyT/wBv3/tvX1VXyr+3P/zJP/b9/wC29AHzhon/AB6v/vn+Qoo0T/j1f/fP8hRQUg8b/wDI465/1+zf+hmvvz4RuP8AhWnhEf8AUJtc/wDfhK+DPGdlcSeLtadI8qbybB3D++as2nijxtZW0NtZ+I9dt7eFQkUUWpSIsagYAUBsAADGBQSfpHb/AOrGTk5Oakr84B41+IIGB4t8SAf9hab/AOLo/wCE2+IP/Q2+JP8AwbTf/F0Afo/RX5wf8Jt8Qf8AobfEn/g2m/8Ai6P+E2+IP/Q2+JP/AAbTf/F0Afo/RX5wf8Jt8Qf+ht8Sf+Dab/4uj/hNviD/ANDb4k/8G03/AMXQB+j9FfnB/wAJt8Qf+ht8Sf8Ag2m/+Lo/4Tb4g/8AQ2+JP/BtN/8AF0Afo/RX5wf8Jt8Qf+ht8Sf+Dab/AOLo/wCE2+IP/Q2+JP8AwbTf/F0Afo/RX5wf8Jt8Qf8AobfEn/g2m/8Ai6P+E2+IP/Q2+JP/AAbTf/F0Afo/RX5wf8Jt8Qf+ht8Sf+Dab/4uj/hNviD/ANDb4k/8G03/AMXQB+j9FfnB/wAJt8Qf+ht8Sf8Ag2m/+Lo/4Tb4g/8AQ2+JP/BtN/8AF0Afo/RX5wf8Jt8Qf+ht8Sf+Dab/AOLo/wCE2+IP/Q2+JP8AwbTf/F0Afo/RX5wf8Jt8Qf8AobfEn/g2m/8Ai6P+E2+IP/Q2+JP/AAbTf/F0Afo/RX5wf8Jt8Qf+ht8Sf+Dab/4uj/hNviD/ANDb4k/8G03/AMXQB+j9FfnB/wAJt8Qf+ht8Sf8Ag2m/+Lo/4Tb4g/8AQ2+JP/BtN/8AF0Afo/RX5wf8Jt8Qf+ht8Sf+Dab/AOLo/wCE2+IP/Q2+JP8AwbTf/F0Afo/RX5wf8Jt8Qf8AobfEn/g2m/8Ai6P+E2+IP/Q2+JP/AAbTf/F0Afo/RX5wf8Jt8Qf+ht8Sf+Dab/4uj/hNviD/ANDb4k/8G03/AMXQB+j9RzzLEhLHmvzk/wCE2+IP/Q2+JP8AwbTf/F0j+M/H7/f8V+I2+uqyn/2egD9DjfvkDaATV6CYSjjg4zX5wf8ACX+O8Af8JR4g4/6ikv8A8XT18aeP1+74r8Rj6arL/wDF0AfpBRX5wf8ACbfEH/obfEn/AINpv/i6P+E2+IP/AENviT/wbTf/ABdAH6P0V+cH/CbfEH/obfEn/g2m/wDi6P8AhNviD/0NviT/AMG03/xdAH6P18q/tz/8yT/2/f8AtvXhX/CbfEH/AKG3xJ/4Npv/AIusrXdT8TeIPI/t7VNS1PyN3lfbbxpvL3Y3bdzHGcDOOuBQBFon/Hq/++f5CipNLhkgt2WVdrFicZz2FFBSP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Forty-eight year old woman with an eight week history of cough, dyspnea with exertion, fatigue, and slight weight loss. Posteroanterior&nbsp;chest radiograph&nbsp;reveals bilateral volume loss with reticular opacities at both bases. There was improvement following&nbsp;glucocorticoid therapy, but the patient did not return to normal lung function or exercise capacity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6096=[""].join("\n");
var outline_f5_61_6096=null;
var title_f5_61_6097="Typical carcinoid RML CT";
var content_f5_61_6097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Typical carcinoid tumor presenting as a RML nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial noncontrasted CT image of a typical bronchial carcinoid involving the right middle lobe (RML). The image on the left, which was obtained with lung-window settings, shows a lobulated nodule in the RML (arrow). The image on the right depicts this mass with mediastinal soft-tissue-window settings, which shows that the nodule is soft tissue density without any calcification and therefore indeterminate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles F Thomas, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6097=[""].join("\n");
var outline_f5_61_6097=null;
var title_f5_61_6098="Calculator: Crohn's disease activity index (CDAI)";
var content_f5_61_6098=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"CDAI_form\" name=\"CDAI_form\" onkeydown=\"document.CDAI_form.cctotal.value='';\" onkeyup=\"CDAI_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Crohn's disease activity index (CDAI)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Patient reported stool pattern",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onchange=\"CDAI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Average number of liquid or soft stools per day over seven days (14 points per stool)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"CDAI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Using diphenoxylate or loperimide for diarrhea (30 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Average abdominal pain rating over seven days",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Mild pain (35 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderate pain (70 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Severe pain (105 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           General well being each day over seven days",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Well (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Slightly below average (49 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Poor (98 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Very poor (147 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Terrible (196 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Complications",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"CDAI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Arthritis or arthralgia (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"CDAI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Iritis or uveitis (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"CDAI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Erythema nodosum, pyoderma gangrenosum or aphthous stomatitis (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"CDAI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Anal fissure, fistula or abcess (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"CDAI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Other fistula (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"CDAI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Temperature over 100 &deg;F (37.8 &deg;C) in the last week (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Finding of an abdominal mass",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc11\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           No mass (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc11\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Possible mass (20 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc11\" onclick=\"CDAI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Definite mass (50 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Anemia and weight change",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc12\" onchange=\"CDAI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Absolute deviation of hematocrit from 47% in males or 42% in females (6 points per percent deviation)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc13\" onchange=\"CDAI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Percentage deviation from standard weight (1 point for each percent deviation)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          CDAI Interpretation",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"          <span class=\"medCalcFontOneBold\">",
"           0-149 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Asymptomatic remission",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"          <span class=\"medCalcFontOneBold\">",
"           150-220 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Mildly to moderately active Crohn's disease",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"          <span class=\"medCalcFontOneBold\">",
"           221-450 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Moderately to severely active Crohn's disease",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"          <span class=\"medCalcFontOneBold\">",
"           451-1100 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Severely active to fulminant disease",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <div id=\"calc_hints\">",
"    <span class=\"medCalcFontOne\">",
"    </span>",
"   </div>",
"   <div id=\"calc_notes\">",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      Patients requiring steroids to remain asymptomatic are not considered to be in remission but are referred to as being \"steroid dependent.\"",
"     </li>",
"     <li>",
"      Absolute deviation of hematocrit is simply the difference in hematocrit from standard.  A male patient with a hematocrit of 40% has an absolute deviation of 7.",
"     </li>",
"     <li>",
"      Percent deviation from standard weight is (1 - weight/standard weight) * 100, thus positive percent deviation represents weight loss, adding points to the CDAI.",
"     </li>",
"     <li>",
"      Please see appropriate UpToDate topic reviews for further information.",
"     </li>",
"    </ul>",
"   </div>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <div id=\"calc_refs\">",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index.",
"       <i>",
"        Inflamm Bowel Dis",
"       </i>",
"       . 2006 Apr;12(4):304-10.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index.  National Cooperative Crohn's Disease Study.",
"       <i>",
"        Gastroenterology",
"       </i>",
"       . 1976 Mar;70(3):439-44.",
"      </span>",
"     </li>",
"    </ol>",
"   </div>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"CDAI_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6098=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function CDAI_fx() {",
"with(document.CDAI_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"thisvalue = parseFloat(cc1.value);",
"if (isNaN(thisvalue)) thisvalue = 0;",
"ThisScore =  thisvalue * 14 + 0;",
"Score =  Score + ThisScore;",
"if (cc2.checked){",
"Score = Score + 30;",
"}",
"if (cc3[0].checked){",
"Score = Score + 0;",
"}",
"if (cc3[1].checked){",
"Score = Score + 35;",
"}",
"if (cc3[2].checked){",
"Score = Score + 70;",
"}",
"if (cc3[3].checked){",
"Score = Score + 105;",
"}",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 49;",
"}",
"if (cc4[2].checked){",
"Score = Score + 98;",
"}",
"if (cc4[3].checked){",
"Score = Score + 147;",
"}",
"if (cc4[4].checked){",
"Score = Score + 196;",
"}",
"if (cc5.checked){",
"Score = Score + 20;",
"}",
"if (cc6.checked){",
"Score = Score + 20;",
"}",
"if (cc7.checked){",
"Score = Score + 20;",
"}",
"if (cc8.checked){",
"Score = Score + 20;",
"}",
"if (cc9.checked){",
"Score = Score + 20;",
"}",
"if (cc10.checked){",
"Score = Score + 20;",
"}",
"if (cc11[0].checked){",
"Score = Score + 0;",
"}",
"if (cc11[1].checked){",
"Score = Score + 20;",
"}",
"if (cc11[2].checked){",
"Score = Score + 50;",
"}",
"thisvalue = parseFloat(cc12.value);",
"if (isNaN(thisvalue)) thisvalue = 0;",
"ThisScore =  thisvalue * 6 + 0;",
"Score =  Score + ThisScore;",
"thisvalue = parseFloat(cc13.value);",
"if (isNaN(thisvalue)) thisvalue = 0;",
"ThisScore =  thisvalue * 1 + 0;",
"Score =  Score + ThisScore;",
"cctotal.value = Score;",
"",
"if (doCalc){",
"",
"rrclr();",
"if ((Score >= 0) && (Score <= 149)){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 150) && (Score <= 220)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 221) && (Score <= 450)){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 451) && (Score <= 1100)){ document.getElementById('rr1_4').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f5_61_6098=null;
var title_f5_61_6099="Patient information: Cushing's syndrome (The Basics)";
var content_f5_61_6099=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15600\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/50/27424\">",
"         Endocrine glands",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/38/7791\">",
"          Changes caused by Cushing's syndrome",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/52/5967\">",
"           Stretch marks caused by Cushing's syndrome",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/4/36930\">",
"         Patient information: Absent or irregular periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/12/1218\">",
"         Patient information: Acne (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/26/20898\">",
"         Patient information: Addison&rsquo;s disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/58/35746\">",
"         Patient information: Osteoporosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/28/7619\">",
"         Patient information: Pituitary adenoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/0/9220\">",
"         Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/19/13619\">",
"         Patient information: Cushing's syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/47/10994\">",
"         Patient information: Cushing's syndrome treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cushing's syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cushings-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H630346111\">",
"      <span class=\"h1\">",
"       What is Cushing&rsquo;s syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cushing&rsquo;s syndrome is a condition that can cause lots of different medical problems, including weight gain, bone and muscle weakness, and high blood pressure.",
"     </p>",
"     <p>",
"      Cushing&rsquo;s syndrome occurs when a person has too much &ldquo;cortisol&rdquo; in his or her body. Cortisol is a hormone that helps the body to work normally. But when people have too much cortisol, they can get symptoms.",
"     </p>",
"     <p>",
"      Cortisol is made in the adrenal glands, small organs that are located on top of each kidney (",
"      <a class=\"graphic graphic_figure graphicRef67279 \" href=\"UTD.htm?26/50/27424\">",
"       figure 1",
"      </a>",
"      ). Normally, the adrenal glands make cortisol after they receive signals from the pituitary gland. The pituitary gland is a small organ that is located just below the brain.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H630346118\">",
"      <span class=\"h1\">",
"       What are the causes of Cushing&rsquo;s syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cushing&rsquo;s syndrome can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines that act like cortisol, also called steroids &ndash; People might take high doses of these medicines for asthma or some types of arthritis. These medicines are different than the steroids athletes take to build muscle.",
"       </li>",
"       <li>",
"        Abnormal growths in the pituitary gland or other parts of the body &ndash; These can signal the adrenal glands to make too much cortisol.",
"       </li>",
"       <li>",
"        Problems in the adrenal glands that cause them to make too much cortisol.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H630346125\">",
"      <span class=\"h1\">",
"       What are the symptoms of Cushing&rsquo;s syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with Cushing&rsquo;s syndrome can have one or more of the following symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Weight gain in the face, neck, back, or belly (",
"        <a class=\"graphic graphic_picture graphicRef65766 \" href=\"UTD.htm?7/38/7791\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Thin skin that bruises easily. People can also have reddish-purple stretch marks (",
"        <a class=\"graphic graphic_picture graphicRef59758 \" href=\"UTD.htm?5/52/5967\">",
"         picture 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Absent or irregular monthly periods (in women)",
"       </li>",
"       <li>",
"        Increased hair growth, oily skin, or acne",
"       </li>",
"       <li>",
"        Weak muscles in the upper arms or legs. For example, people can have trouble getting out of a chair.",
"       </li>",
"       <li>",
"        Bones that can break more easily than normal",
"       </li>",
"       <li>",
"        Diabetes (high blood sugar levels)",
"       </li>",
"       <li>",
"        High blood pressure and heart problems",
"       </li>",
"       <li>",
"        Changes in mood, such as feeling depressed, worried, or angry",
"       </li>",
"       <li>",
"        Getting infections more easily",
"       </li>",
"       <li>",
"        Blood clots in the veins in the legs",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Different people can have different symptoms. If symptoms are not treated, they can get worse over time and become life-threatening.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H630346132\">",
"      <span class=\"h1\">",
"       Is there a test for Cushing&rsquo;s syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will talk with you and do an exam. He or she will also do lab tests to measure the cortisol levels in your urine, blood, or saliva. If your cortisol levels are high, you will need more tests to figure out which treatment is right for you. These tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        CT or MRI scans of your pituitary gland or adrenal glands, or other imaging tests &ndash; Imaging tests can create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H630346139\">",
"      <span class=\"h1\">",
"       How is Cushing&rsquo;s syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for Cushing&rsquo;s syndrome depends on the cause. If you have symptoms because you take high doses of steroids, your doctor will slowly reduce your dose.",
"     </p>",
"     <p>",
"      If you do not take steroids, treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery &ndash; Doctors can do different types of surgery to remove:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Abnormal growths in the pituitary gland or other parts of the body",
"       </li>",
"       <li>",
"        One or both of the adrenal glands",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Radiation therapy &ndash; Radiation can kill abnormally-growing cells.",
"       </li>",
"       <li>",
"        Medicines &ndash; Different medicines can stop the adrenal glands from making too much cortisol.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H630346146\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with Cushing&rsquo;s syndrome can be cured with treatment. But some people will need to take medicine every day for the rest of their lives to stay healthy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H630346153\">",
"      <span class=\"h1\">",
"       What if I am pregnant and have symptoms of Cushing&rsquo;s syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant and have symptoms of Cushing&rsquo;s syndrome, talk with your doctor or nurse. Pregnant women with Cushing&rsquo;s syndrome need treatment. The disorder can lead to problems during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H630346160\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=see_link\">",
"       Patient information: Acne (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"       Patient information: Osteoporosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=see_link\">",
"       Patient information: Absent or irregular periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/26/20898?source=see_link\">",
"       Patient information: Addison&rsquo;s disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=see_link\">",
"       Patient information: Pituitary adenoma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=see_link\">",
"       Patient information: Cushing's syndrome (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/47/10994?source=see_link\">",
"       Patient information: Cushing's syndrome treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/0/9220?source=see_link\">",
"       Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/61/6099?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15600 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6099=[""].join("\n");
var outline_f5_61_6099=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630346111\">",
"      What is Cushing&rsquo;s syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630346118\">",
"      What are the causes of Cushing&rsquo;s syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630346125\">",
"      What are the symptoms of Cushing&rsquo;s syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630346132\">",
"      Is there a test for Cushing&rsquo;s syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630346139\">",
"      How is Cushing&rsquo;s syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630346146\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630346153\">",
"      What if I am pregnant and have symptoms of Cushing&rsquo;s syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630346160\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15600\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/50/27424\">",
"      Endocrine glands",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/38/7791\">",
"       Changes caused by Cushing's syndrome",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/52/5967\">",
"        Stretch marks caused by Cushing's syndrome",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=related_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=related_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/26/20898?source=related_link\">",
"      Patient information: Addison&rsquo;s disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/0/9220?source=related_link\">",
"      Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=related_link\">",
"      Patient information: Cushing's syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/47/10994?source=related_link\">",
"      Patient information: Cushing's syndrome treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=related_link\">",
"      Patient information: Pituitary adenoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_61_6100="Assess LV volume and function 3";
var content_f5_61_6100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Accuracy of RT3DE measurements of LV volume",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of LV volume time curves obtained in one patient from RT3DE and MR images. Results of linear regression (bottom, left) and Bland-Altman (bottom, right) analyses of the point-by-point measurements of LV volume obtained in 16 patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Mor-Avi V, Sugeng L, Weinert L, et al. Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: comparison with magnetic resonance imaging. Circulation 2004; 110:1814.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6100=[""].join("\n");
var outline_f5_61_6100=null;
var title_f5_61_6101="Lovastatin: Patient drug information";
var content_f5_61_6101=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lovastatin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     see \"Lovastatin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/47/42743?source=see_link\">",
"     see \"Lovastatin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altoprev&reg;;",
"     </li>",
"     <li>",
"      Mevacor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lovastatin&reg;;",
"     </li>",
"     <li>",
"      CO Lovastatin;",
"     </li>",
"     <li>",
"      Dom-Lovastatin;",
"     </li>",
"     <li>",
"      Gen-Lovastatin;",
"     </li>",
"     <li>",
"      Mevacor&reg;;",
"     </li>",
"     <li>",
"      Mylan-Lovastatin;",
"     </li>",
"     <li>",
"      Novo-Lovastatin;",
"     </li>",
"     <li>",
"      Nu-Lovastatin;",
"     </li>",
"     <li>",
"      PHL-Lovastatin;",
"     </li>",
"     <li>",
"      PMS-Lovastatin;",
"     </li>",
"     <li>",
"      PRO-Lovastatin;",
"     </li>",
"     <li>",
"      RAN&trade;-Lovastatin;",
"     </li>",
"     <li>",
"      ratio-Lovastatin;",
"     </li>",
"     <li>",
"      Riva-Lovastatin;",
"     </li>",
"     <li>",
"      Sandoz-Lovastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to slow the progress of heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lovastatin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Active liver disease or a rise in liver enzymes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain in the upper, right side.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fast release products: Take at dinner.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695773",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take long-acting products on an empty stomach at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10823 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6101=[""].join("\n");
var outline_f5_61_6101=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190412\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190413\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020105\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020107\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020106\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020111\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020112\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020114\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020109\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020110\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020115\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020116\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=related_link\">",
"      Lovastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/47/42743?source=related_link\">",
"      Lovastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_61_6102="Griseofulvin: Drug information";
var content_f5_61_6102=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Griseofulvin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/56/38789?source=see_link\">",
"    see \"Griseofulvin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/45/33492?source=see_link\">",
"    see \"Griseofulvin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Grifulvin V&reg;;",
"     </li>",
"     <li>",
"      Gris-PEG&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Tinea infections:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Microsize:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea corporis, tinea cruris, tinea capitis: 500 mg daily in single or divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea pedis, tinea unguium: 1000 mg daily in single or divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Ultramicrosize:",
"      </i>",
"     </b>",
"     375 mg daily in single or divided doses; doses up to 750 mg daily in divided doses have been used for infections more difficult to eradicate such as tinea unguium and tinea pedis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Duration of therapy depends on the site of infection:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea corporis: 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea cruris: 2-6 weeks (Red Book, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea capitis: 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea pedis: 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea unguium: 4-6 months or longer",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F177541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/45/33492?source=see_link\">",
"      see \"Griseofulvin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Tinea infections:",
"     </b>",
"     Oral: Children &gt;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Microsize:",
"      </i>",
"     </b>",
"     10-20 mg/kg/day in single or 2 divided doses (maximum: 1000 mg daily) (Red Book, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea capitis: Higher dosages (20-25 mg/kg/day) have been recommended (Ali, 2007; Lipozenic, 2002; Sethi, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Ultramicrosize:",
"      </i>",
"     </b>",
"     5-15 mg/kg/day in single dose or 2 divided doses (maximum: 750 mg daily) (Red Book, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Duration of therapy depends on the site of infection:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea corporis: 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea cruris: 2-6 weeks (Red Book, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea capitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's labeling: 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternate recommendations: Children: 6-12 weeks; use up to 16 weeks may be required (AAP Red Book&reg; recommends continuing treatment for 2 weeks after clinical resolution of symptoms) (Ali, 2007; Lipozenic, 2002; Sethi, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea pedis: 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea unguium: 4-6 months or longer",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F177526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [microsize]: 125 mg/5 mL (118 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [microsize]: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grifulvin V&reg;: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [ultramicrosize]: 125 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gris-PEG&reg;: 125 mg, 250 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F177505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with a fatty meal (peanut butter or ice cream) to increase absorption, or with food or milk to avoid GI upset (Red Book, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gris-PEG&reg; tablets: May be swallowed whole or crushed and sprinkled onto 1 tablespoonful of applesauce and swallowed immediately without chewing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension: Shake well before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of tinea infections of the skin, hair, and nails caused by susceptible species of",
"     <i>",
"      Microsporum, Epidermophyton,",
"     </i>",
"     or",
"     <i>",
"      Trichophyton",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache, insomnia, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema (rare),  erythema multiforme-like drug reaction, photosensitivity, rash (most common), urticaria (most common),",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, epigastric distress, GI bleeding, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Granulocytopenia, leukopenia (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrosis, proteinuria (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Drug-induced lupus-like syndrome (rare), oral thrush",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Bilirubin increased, liver transaminases increased, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to griseofulvin or any component of the formulation; liver failure; porphyria; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Discontinue therapy if granulocytopenia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: May cause jaundice and elevated liver function tests or bilirubin (may be serious or even fatal); discontinue therapy if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Hypersensitivity cross reaction between penicillins and griseofulvin is possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Avoid exposure to intense sunlight to prevent photosensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: Severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme) have been reported (may be serious or even fatal); discontinue use if severe skin reactions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use for the prophylaxis of fungal infections has not been established; not effective for the treatment of tinea versicolor.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F177554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate), CYP2C9 (weak/moderate), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Griseofulvin may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Griseofulvin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Methohexital; Thiopental.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Griseofulvin may increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Griseofulvin may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Griseofulvin may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Griseofulvin may decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F177516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Concomitant use will also cause a \"disulfiram\"-type reaction consisting of tachycardia, flushing, headache, nausea, and in some patients, vomiting and chest and/or abdominal pain. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Griseofulvin concentrations may be increased if taken with food, especially with high-fat meals. Management: Take with a fatty meal (peanuts or ice cream) to increase absorption, or with food or milk to avoid GI upset.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4293494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. Griseofulvin crosses the placenta. Because adverse events have also been observed in humans (two cases of conjoined twins), use during pregnancy is contraindicated. Effective contraception should be used during therapy and for 1 month after therapy is discontinued in women of reproductive potential.  Men should avoid fathering a child for at least 6 months after therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F177530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if griseofulvin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering griseofulvin to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F177510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Griseofulvin Microsize Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (120 mL): $41.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Grifulvin V Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $907.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gris-PEG Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (100): $620.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $791.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Griseofulvin Microsize Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $771.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Griseofulvin Ultramicrosize Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (100): $575.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $733.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F177500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal, hepatic, and hematopoietic function tests especially with long-term use",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F177511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biogrisin (PL);",
"     </li>",
"     <li>",
"      Delmofulvina (IT);",
"     </li>",
"     <li>",
"      Fulcin (BR, EC, ES, FI, IT, NO, PT);",
"     </li>",
"     <li>",
"      Fulcin Forte (MX);",
"     </li>",
"     <li>",
"      Fulcin S (DE);",
"     </li>",
"     <li>",
"      Fulsovin (GB);",
"     </li>",
"     <li>",
"      Fulvicina (ES);",
"     </li>",
"     <li>",
"      Fungistop (ID);",
"     </li>",
"     <li>",
"      Fungivin (NO, PK);",
"     </li>",
"     <li>",
"      Greosin (ES);",
"     </li>",
"     <li>",
"      Gricin (CZ, DE, HU, PL);",
"     </li>",
"     <li>",
"      Grifulin Forte (IL);",
"     </li>",
"     <li>",
"      Grifulvin (TH);",
"     </li>",
"     <li>",
"      Grisefuline (FR);",
"     </li>",
"     <li>",
"      Grisen (TW);",
"     </li>",
"     <li>",
"      Grisenova (GR);",
"     </li>",
"     <li>",
"      griseo von ct (DE);",
"     </li>",
"     <li>",
"      Griseofulvin (HN, IE, PL);",
"     </li>",
"     <li>",
"      Griseofulvin Leo (LU);",
"     </li>",
"     <li>",
"      Griseofulvin Prafa (ID);",
"     </li>",
"     <li>",
"      Griseofulvina (IT);",
"     </li>",
"     <li>",
"      Griseomed (AT);",
"     </li>",
"     <li>",
"      Grisflavin (TH);",
"     </li>",
"     <li>",
"      Grisfulvin V (PH);",
"     </li>",
"     <li>",
"      Grisol (CH);",
"     </li>",
"     <li>",
"      Grisomicon (PT);",
"     </li>",
"     <li>",
"      Grisoral (IN);",
"     </li>",
"     <li>",
"      Grisovin (AE, AT, AU, BH, CO, CY, CZ, EG, IQ, IR, JO, KW, LB, LY, MX, OM, PE, PT, QA, SA, SY, VE, YE);",
"     </li>",
"     <li>",
"      Grisovin-FP (AR, PH, UY);",
"     </li>",
"     <li>",
"      Grisovina FP (IT);",
"     </li>",
"     <li>",
"      Grisuven (HK);",
"     </li>",
"     <li>",
"      Grisuvin (MY);",
"     </li>",
"     <li>",
"      Grivin (MY, TH);",
"     </li>",
"     <li>",
"      Grivin Forte (ID);",
"     </li>",
"     <li>",
"      Krisovin (MY, SG);",
"     </li>",
"     <li>",
"      Likuden (DE);",
"     </li>",
"     <li>",
"      Microcidal (ZA);",
"     </li>",
"     <li>",
"      Ponzyr V (KP);",
"     </li>",
"     <li>",
"      Rexavin (ID);",
"     </li>",
"     <li>",
"      Sulvina (ES);",
"     </li>",
"     <li>",
"      Trivanex (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F177490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits fungal cell mitosis at metaphase; binds to human keratin making it resistant to fungal invasion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F177507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Ultramicrosize griseofulvin absorption is almost complete; absorption of microsize griseofulvin is variable; enhanced by ingestion of a fatty meal (GI absorption of ultramicrosize is ~1.5 times that of microsize)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~1.5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 9-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine; feces; perspiration",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ali S, Graham TA, and Forgie SE, \"The Assessment and Management of Tinea Capitis in Children,\"",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2007, 23(9):662-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/17876261/pubmed\" id=\"17876261\" target=\"_blank\">",
"        17876261",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Araujo OE, Flowers FP, and King MM, \"Griseofulvin: A New Look at an Old Drug,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1990, 24(9):851-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/2260345/pubmed\" id=\"2260345\" target=\"_blank\">",
"        2260345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleece D, Gaughan JP, and Aronoff SC, &ldquo;Griseofulvin Versus Terbinafine in the Treatment of Tinea Capitis: A Meta-Analysis of Randomized, Clinical Trials,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(5):1312-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/15520113/pubmed\" id=\"15520113\" target=\"_blank\">",
"        15520113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuller LC, Smith CH, Cerio R, et al, &ldquo;A Randomized Comparison of 4 Weeks of Terbinafine vs 8 Weeks of Griseofulvin for the Treatment of Tinea Capitis,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2001, 144(2):321-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/11251566/pubmed\" id=\"11251566\" target=\"_blank\">",
"        11251566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ginsburg CM, McCracken GH Jr, Petruska M, et al, &ldquo;Effect of Feeding on Bioavailability of Griseofulvin in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1983, 102(2):309-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/6822943/pubmed\" id=\"6822943\" target=\"_blank\">",
"        6822943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kawabe Y, Mizuno N, Miwa N, et al, &ldquo;Photosensitivity Induced by Griseofulvin,&rdquo;",
"      <i>",
"       Photodermatol",
"      </i>",
"      , 1988, 5(6):272-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/3249685/pubmed\" id=\"3249685\" target=\"_blank\">",
"        3249685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lecky BR, &ldquo;Griseofulvin-Induced Neuropathy,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1990, 335(8683):230-1.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis RE, \"Current Concepts in Antifungal Pharmacology,\"",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2011, 86(8):805-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/21803962/pubmed\" id=\"21803962\" target=\"_blank\">",
"        21803962",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipozencic J, Skerlev M, Orofino-Costa R, et al, &ldquo;A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study of Oral Terbinafine and Open-Label, High-Dose Griseofulvin in Children With Tinea Capitis due to",
"      <i>",
"       Microsporum",
"      </i>",
"      Species,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2002, 146(5):816-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/12000378/pubmed\" id=\"12000378\" target=\"_blank\">",
"        12000378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mion G, Verdon R, Le Gulluche Y, et al, &ldquo;Fatal Toxic Epidermal Necrolysis After Griseofulvin,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1989, 2(8675):1331.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pacifici GM, \"Placental Transfer of Antibiotics Administered to the Mother: A Review,\"",
"      <i>",
"       Int J Clin Pharmacol Ther",
"      </i>",
"      ,  2006, 44(2):57-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/16502764/pubmed\" id=\"16502764\" target=\"_blank\">",
"        16502764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pomeranz AJ and Sabnis SS, &ldquo;Tinea Capitis: Epidemiology, Diagnosis and Management Strategies,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2002, 4(12):779-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/12431130/pubmed\" id=\"12431130\" target=\"_blank\">",
"        12431130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book&reg;: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 29th ed, Pickering LK, ed. Elk  Grove Village, IL: American Academy of Pediatrics, 2012, 712-4; 832t.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sethi A and Antaya R, \"Systemic Antifungal Therapy for Cutaneous Infections in Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2006, 25(7):643-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/16804437/pubmed\" id=\"16804437\" target=\"_blank\">",
"        16804437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sladden MJ and Johnston GA, &ldquo;Common Skin Infections in Children,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2004, 329(7457):95-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/15242915/pubmed\" id=\"15242915\" target=\"_blank\">",
"        15242915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trepanier EF and Amsden GW, &ldquo;Current Issues in Onchomycosis,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1998, 32(2):204-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/9496407/pubmed\" id=\"9496407\" target=\"_blank\">",
"        9496407",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo;",
"      <i>",
"       Clin Pharmacokinetics",
"      </i>",
"      , 1988, 15(4):254-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/3191648/pubmed\" id=\"3191648\" target=\"_blank\">",
"        3191648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang DJ and Rankin GO, &ldquo;Nephrotoxicity of Antifungal Agents,&rdquo;",
"      <i>",
"       Adverse Drug React Acute Poisoning Rev",
"      </i>",
"      , 1985, 4(1):37-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/61/6102/abstract-text/3890481/pubmed\" id=\"3890481\" target=\"_blank\">",
"        3890481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8502 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-1B4384F6EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6102=[""].join("\n");
var outline_f5_61_6102=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177520\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177558\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177525\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177541\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177526\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177502\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177487\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177505\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177503\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177556\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177508\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177491\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177554\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177496\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177516\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4293494\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177530\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265843\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177510\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177500\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177511\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177490\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177507\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8502\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8502|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/56/38789?source=related_link\">",
"      Griseofulvin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/45/33492?source=related_link\">",
"      Griseofulvin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_61_6103="Livedoid vasculopathy";
var content_f5_61_6103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Livedoid vasculopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/61/6103/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/61/6103/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/61/6103/contributors\">",
"     Mark DP Davis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/61/6103/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/61/6103/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/61/6103/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/61/6103/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/61/6103/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/61/6103/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Livedoid vasculopathy is a chronic, recurrent, painful skin disorder that involves the distal lower extremities and feet. The disorder is a thrombotic, noninflammatory condition associated with the formation of clots within the lumina of medium-sized arterioles and hyalinizing changes within the subintimal region of involved vessels.",
"   </p>",
"   <p>",
"    Livedoid vasculopathy can occur by itself or in the setting of a variety of systemic disorders, including systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). The disorder has also been linked to a growing list of clotting abnormalities. Livedoid vasculopathy is often misdiagnosed as either chronic venous insufficiency or some form of systemic or cutaneous vasculitis.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of livedoid vasculopathy are presented here. The diagnosis and treatment of chronic venous insufficiency and the diagnosis and treatment of small- and medium-vessel vasculitis of the skin are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=see_link\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature related to livedoid vasculopathy is highly problematic with regard to nomenclature [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/1\">",
"     1",
"    </a>",
"    ]. There are three major sources of confusion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrophie blanche, the descriptive term for the major cutaneous lesions associated with this disorder, is often employed interchangeably with the more appropriate names for the disease entity, livedoid vasculopathy or segmental hyalinizing vasculopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Atrophie blanche'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The terms \"livedoid vasculitis\" or just \"livedo vasculitis\" have been used widely to describe this condition, but in fact the disorder does not involve destructive inflammation within the blood vessel wall and is therefore not a true vasculitis.",
"     </li>",
"     <li>",
"      A host of names for livedoid vasculopathy have been employed in the literature:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Livedo vasculitis",
"     </li>",
"     <li>",
"      Livedoid vasculitis",
"     </li>",
"     <li>",
"      Segmental hyalinizing vasculopathy",
"     </li>",
"     <li>",
"      Livedo reticularis with summer ulcerations",
"     </li>",
"     <li>",
"      Livedo reticularis with winter ulcerations",
"     </li>",
"     <li>",
"      Atrophie blanche en plaque",
"     </li>",
"     <li>",
"      Atrophie blanche",
"     </li>",
"     <li>",
"      Painful purpuric ulcers with reticular patterning on the lower extremities (\"PURPLE\")",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathological changes occur in the blood vessels of the middle and lower dermis, at the level of the sweat glands. Hemorrhage can be observed around the sweat glands, but extravasation of red blood cells is not a constant feature.",
"   </p>",
"   <p>",
"    The blood vessels in livedoid vasculopathy demonstrate thickening and focal thrombosis, with endothelial proliferation and hyaline degeneration of the subintimal layer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/3\">",
"     3",
"    </a>",
"    ]. The hyaline material stains positively by the periodic acid-Schiff technique but is also visualized well on hematoxylin-eosin staining (",
"    <a class=\"graphic graphic_picture graphicRef55773 \" href=\"UTD.htm?12/37/12887\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The elastic laminae of the involved vessels are usually preserved, and the vascular wall is rarely destroyed. However, the lumen is often filled with proliferating cells embedded within loose fibrinoid material. The surrounding inflammatory reaction is relatively mild, and consists primarily of lymphocytes.",
"   </p>",
"   <p>",
"    The histologic findings vary according to the stage of the lesion biopsied [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/4\">",
"     4",
"    </a>",
"    ]. In a study of 16 biopsies from 10 patients, the following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirteen of the biopsies came from early erythematous, telangiectatic, purpuric lesions. Among these lesions, the most striking finding was an eosinophilic-staining fibrinoid material in the walls and lumina of the superficial blood vessels. Many biopsies also demonstrated V-shaped areas of necrosis involving the epidermis and superficial dermis.",
"     </li>",
"     <li>",
"      Three of the biopsies came from white, atrophic, scarred areas. These showed epidermal atrophy and flattening of the rete ridges in the central portions of the sections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lower leg is the most common site of lesions, followed by the ankle [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/5\">",
"     5",
"    </a>",
"    ]. Lesions also occur on the dorsal surface of the foot. Several characteristic skin findings can be noted in livedoid vasculopathy, including changes in the skin that resemble livedo reticularis, atrophie blanche, ulceration, and edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Livedoid changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest stage is represented by the finding of deep, barely palpable, slightly inflammatory nodules that have a linear or angular appearance. These lesions resemble a patchy, incomplete livedo reticularis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Atrophie blanche",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophie blanche was described in 1929 by Milian, who termed the finding atrophie blanche en plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/6\">",
"     6",
"    </a>",
"    ]. This lesion is a smooth, ivory-white plaque-like area surrounded by a hyperpigmented border and telangiectatic blood vessels (",
"    <a class=\"graphic graphic_picture graphicRef82968 \" href=\"UTD.htm?27/62/28644\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef82969 \" href=\"UTD.htm?17/32/17926\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The skin lesions of livedoid vasculopathy can also be noticed first as small, erythematous, telangiectatic, purpuric areas, with scattered petechiae at the margins. They are often slightly raised. Many patients experience substantial pain, burning, or itching from their rash. Some lesions develop a small hemorrhagic central crust.",
"   </p>",
"   <p>",
"    Atrophie blanche has been noted to follow a painful ulcerative stage, but also can occur in the absence of previous ulceration. Most patients with this disease for a sufficient length of time have several white, atrophic scars that were not preceded by gross ulceration. The white atrophic scars are frequently stippled with small amounts of brown pigment.",
"   </p>",
"   <p>",
"    The confinement of atrophie blanche to the lower extremities implies that hydrostatic pressure plays a role in the pathophysiology. This may have therapeutic implications in that leg elevation can contribute to resolution of the skin lesions and perhaps to the avoidance of ulceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial ulcerations are common in livedoid vasculopathy. Removal of the eschar reveals a sharply punched-out, polyangular or stellate lesion. Most measure between 1 mm and 5 mm (",
"    <a class=\"graphic graphic_picture graphicRef52615 \" href=\"UTD.htm?27/8/27791\">",
"     picture 4",
"    </a>",
"    ), but larger, deeper ulcerations sometimes occur. Once an ulcer has become established, the healing time is slow and can require up to six months.",
"   </p>",
"   <p>",
"    In contrast to the ulcerations of stasis dermatitis, the ulcerations of livedoid vasculopathy have no predilection for the malleolar regions but can occur anywhere on the lower legs, ankles, and dorsal surfaces of the feet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema in the ankle region can precede the onset of clinical lesions by one to two weeks. The edema can be associated with an aching pain, followed by the onset of red, angular and linear lesions on the legs, ankles, and insteps. The etiology of this edema is obscure, but it does not appear to be related to varicose veins or thrombophlebitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Livedoid vasculopathy can occur with or without identifiable predisposing hypercoagulable risk factors. It can also occur in the setting of a defined illness, particularly connective tissue disorders. The types of connective tissue diseases most commonly diagnosed in the setting of livedoid vasculopathy are the primary antiphospholipid syndrome, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, mixed connective tissue disease, and undifferentiated connective tissue disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HYPERCOAGULABLE RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Livedoid vasculopathy has been linked to a growing number of risk factors for hypercoagulability. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiphospholipid antibodies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\", section on 'The antibodies'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anticardiolipin antibodies",
"     </li>",
"     <li>",
"      Lupus anticoagulants",
"     </li>",
"     <li>",
"      Antibodies to beta-2-glycoprotein-1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dysproteinemias (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cryoglobulins",
"     </li>",
"     <li>",
"      Cryofibrinogens",
"     </li>",
"     <li>",
"      Waldenstrom's macroglobulinemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic disorders predisposing to thrombosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"       \"Overview of the causes of venous thrombosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Factor V Leiden mutation",
"     </li>",
"     <li>",
"      Protein C deficiency",
"     </li>",
"     <li>",
"      Protein S deficiency",
"     </li>",
"     <li>",
"      Hyperhomocysteinemia",
"     </li>",
"     <li>",
"      Prothrombin gene mutation (G20210A)",
"     </li>",
"     <li>",
"      Methylenetetrahydrofolate reductase C677T mutation",
"     </li>",
"     <li>",
"      Plasminogen activator inhibitor-I promoter homozygosity",
"      <span class=\"nowrap\">",
"       (4G/4G)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that new risk factors linking a predisposition to hypercoagulability and the development of livedoid vasculopathy will be described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of livedoid vasculopathy includes a broad array of conditions that have the propensity to cause livedo patterns of skin discoloration, cutaneous ulcers, and nodules of the lower extremities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic venous stasis",
"     </li>",
"     <li>",
"      Peripheral vascular disease",
"     </li>",
"     <li>",
"      Polyarteritis nodosa",
"     </li>",
"     <li>",
"      Medium-vessel vasculitis associated with antineutrophil cytoplasmic antibodies",
"     </li>",
"     <li>",
"      Mixed cryoglobulinemia",
"     </li>",
"     <li>",
"      Pyoderma gangrenosum",
"     </li>",
"     <li>",
"      Buerger's disease",
"     </li>",
"     <li>",
"      Lymphocytic thrombophilic arteritis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Factitial or traumatic disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A skin biopsy is essential to confirmation of the diagnosis; ideally, a fusiform incisional biopsy to include fat should be performed. The optimal sites for biopsy are at the edge of a new ulceration or over a new purpuric patch. The biopsy must be performed deeply enough to include muscular vessels.",
"   </p>",
"   <p>",
"    After the diagnosis has been confirmed histopathologically, an underlying disorder must be excluded. A full history and physical examination must be performed, along with a complete blood count, serum chemistry profile, and urinalysis. There should be two foci of the evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excluding a connective tissue disease",
"     </li>",
"     <li>",
"      Excluding predisposing factors for hypercoagulability",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Excluding connective tissue diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following serological evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythrocyte sedimentation rate and C-reactive protein. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"       \"Acute phase reactants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rheumatoid factor and antibodies to cyclic citrullinated peptides. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"       \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antinuclear antibody testing &ndash; A strongly positive antinuclear antibody (ANA) assay should be followed by additional serological testing to determine the specific disease state responsible for the ANA positivity. This additional testing may include antibodies to double-stranded DNA, and antibodies to the Ro, La, Sm, or RNP antigens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"       \"Measurement and clinical significance of antinuclear antibodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum complement levels &ndash; CH50, C3, and C4. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=see_link\">",
"       \"Overview and clinical assessment of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cryoglobulins &ndash; Blood collected for determination of cryoglobulins should be drawn into prewarmed tubes, allowed to clot, and centrifuged in a temperature controlled setting (preferably at 37 degree C). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Excluding known hypercoagulability risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple risk factors for hypercoagulability have been linked with the development of livedoid vasculopathy. More than one risk factor is identified in some patients.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anticardiolipin antibodies",
"     </li>",
"     <li>",
"      Antithrombin III (functional and immunologic levels)",
"     </li>",
"     <li>",
"      Lupus anticoagulant",
"     </li>",
"     <li>",
"      Antibodies to beta-2-glycoprotein-1",
"     </li>",
"     <li>",
"      Factor V Leiden (R506Q) mutation",
"     </li>",
"     <li>",
"      Protein C deficiency (functional and immunologic levels)",
"     </li>",
"     <li>",
"      Protein S deficiency (functional and immunologic levels)",
"     </li>",
"     <li>",
"      Hyperhomocysteinemia",
"     </li>",
"     <li>",
"      Prothrombin gene mutation (G20210A)",
"     </li>",
"     <li>",
"      Methylenetetrahydrofolate reductase C677T mutation",
"     </li>",
"     <li>",
"      Plasminogen activator inhibitor-I promoter homozygosity",
"      <span class=\"nowrap\">",
"       (4G/4G)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many interventions have been reported to be effective in some patients with livedoid vasculopathy. However, given that livedoid vasculopathy is a syndrome rather than a specific disease caused by a single perturbation, no therapy is effective for all patients. To some degree, all therapeutic approaches to livedoid vasculopathy are empiric. Combinations of treatments must be considered in some patients if initial approaches are unsuccessful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leg elevation, wound care, analgesia, and avoidance of potentially exacerbating exposures and physical factors that may increase the risk of thrombosis comprise interventions that are generally recommended.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wound care &ndash; Control of any superinfection of the wound and maintenance of a moist wound environment are important facets. Rest and elevation help to minimize edema [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Analgesia &ndash; Skin lesions may be very painful. Use of analgesics, including opioids may be necessary for pain control.",
"     </li>",
"     <li>",
"      Control of factors predisposing to thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acquired factors &ndash; Patients who smoke or use tobacco products should be encouraged to quit. Women using hormonal contraceptives which increase the risk of thrombotic disorders should be offered alternative forms of contraception. Stasis should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Address hypercoagulability risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;If feasible, any acquired or heritable diseases or disorders that cause an increased risk of thrombosis should be treated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acquired diseases &ndash; Usual management of diseases or disorders causing a hypercoagulable state should be carried out: malignancy, APS, SLE, or related connective tissue disease. (See appropriate topics).",
"     </li>",
"     <li>",
"      Inherited factors &ndash; If one or more heritable hypercoagulable states is present (eg, hyperhomocysteinemia, factor V leiden deficiency, protein C and S deficiency) treatment for the underlying disorder(s) may be useful [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/2,11\">",
"       2,11",
"      </a>",
"      ]. (See appropriate topics).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Empiric therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence supporting any of the therapies discussed below comes from small, uncontrolled observational studies. We are not aware of any randomized trials of any of the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Antiplatelet therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      : described in combination with other treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       Dipyridamole",
"      </a>",
"      : described in combination with other treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      : three case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/13-15\">",
"       13-15",
"      </a>",
"      ];",
"     </li>",
"     <li>",
"      Low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      : two cases [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or vitamin K antagonist (fluindione): 14 of 16 patients improved [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Fibrinolysis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue plasminogen activator (low dose over two weeks): five of six patients healed [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/17\">",
"       17",
"      </a>",
"      ]; case report healed [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Other treatments",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       Pentoxifylline",
"      </a>",
"      : temporary improvement described in six patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/19\">",
"       19",
"      </a>",
"      ]; eight patients (three healed, four improved) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       Danazol",
"      </a>",
"      low-dose (200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      orally): six of seven patients improved [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperbaric oxygen: Eight of eight patients healed temporarily; six relapsed after discontinuation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulsed intravenous immunoglobulin: Nine of nine patients reported to be improved [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       Iloprost",
"      </a>",
"      (a prostacyclin analog): case report [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ketanserin: case report (healed) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PUVA: eight of eight patients healed; four of four responded [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Niacin (nicotinic acid): 9 of 12 patients healed [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sulfapyridine: 6 of 11 patients healed [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Guanethidine: three of eight patients healed [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6103/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Livedoid vasculopathy is a chronic, recurrent, painful skin disorder that involves the distal lower extremities and feet. The disorder is primarily a thrombotic condition associated with the formation of clots within the lumina of medium-sized arterioles and hyalinizing changes within the subintimal region of involved vessels.",
"     </li>",
"     <li>",
"      Livedoid vasculopathy can occur by itself or in the setting of a variety of underlying systemic disorders, including systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Disease associations'",
"      </a>",
"      above.) The disorder has also been linked to a growing list of acquired and genetically inherited clotting abnormalities, which are often multiple. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hypercoagulable risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features that are common in the lower extremities include painful ulceration, scars (atrophie blanche), and livedoid changes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A skin biopsy is essential to confirmation of the diagnosis; ideally, a fusiform incisional biopsy to include fat should be performed. The optimal sites for biopsy are at the edge of a new ulceration or over a new purpuric patch. The biopsy must be performed deeply enough to include muscular vessels. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two principal pathologic features are a segmental hyalinizing vasculopathy and thrombus formation in blood vessels of the mid- to deep dermis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management includes both general measures and therapy targeting any acquired or inherited diseases or disorders that predispose to thrombosis.",
"     </li>",
"     <li>",
"      General measures include leg elevation, avoiding cigarette smoking and avoiding hormonal contraceptive agents. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For livedoid vasculopathy patients with histories of clinical events consistent with the antiphospholipid syndrome, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      as the initial treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who have antiphospholipid antibodies but no previous manifestations of the antiphospholipid syndrome, we suggest the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with elevated levels of homocysteine or a mutation of methylenetetrahydrofolate reductase, we suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      be included as part of the initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with protein C, protein S, or factor V Leiden deficiencies who have had other clinical events attributable to these risk factors, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      as the initial treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients who have not had such clinical events,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and other therapies may be tried first, reserving warfarin for patients whose disease is refractory to those treatments. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"       \"Management of inherited thrombophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Various treatments have been tried, some with apparent benefit. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Other treatments'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/1\">",
"      Jorizzo JL. Livedoid vasculopathy: what is it? Arch Dermatol 1998; 134:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/2\">",
"      Callen JP. Livedoid vasculopathy: what it is and how the patient should be evaluated and treated. Arch Dermatol 2006; 142:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/3\">",
"      Bard JW, Winkelmann RK. Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis. Arch Dermatol 1967; 96:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/4\">",
"      Gray HR, Graham JH, Johnson W, Burgoon CF Jr. Atrophie blanche: periodic painful ulcers of lower extremities. A clinical and histopathological entity. Arch Dermatol 1966; 93:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/5\">",
"      Hairston BR, Davis MD, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol 2006; 142:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/6\">",
"      Milian G. Les Atrophies Cutanees Syphilitiques. Bull Soc Franc Derm Syph 1929; 36:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/7\">",
"      Alegre VA, Gastineau DA, Winkelmann RK. Skin lesions associated with circulating lupus anticoagulant. Br J Dermatol 1989; 120:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/8\">",
"      Grob JJ, Bonerandi JJ. Thrombotic skin disease as a marker of the anticardiolipin syndrome. Livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity. J Am Acad Dermatol 1989; 20:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/9\">",
"      Lee JS, Kossard S, McGrath MA. Lymphocytic thrombophilic arteritis: a newly described medium-sized vessel arteritis of the skin. Arch Dermatol 2008; 144:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/10\">",
"      Yang LJ, Chan HL, Chen SY, et al. Atrophie blanche. A clinicopathological study of 27 patients. Changgeng Yi Xue Za Zhi 1991; 14:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/11\">",
"      Franc&egrave;s C, Barete S. Difficult management of livedoid vasculopathy. Arch Dermatol 2004; 140:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/12\">",
"      Drucker CR, Duncan WC. Antiplatelet therapy in atrophie blanche and livedo vasculitis. J Am Acad Dermatol 1982; 7:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/13\">",
"      Davis MD, Wysokinski WE. Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin. J Am Acad Dermatol 2008; 58:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/14\">",
"      Kavala M, Kocaturk E, Zindanci I, et al. A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin. J Dermatolog Treat 2008; 19:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/15\">",
"      Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 2006; 142:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/16\">",
"      Hairston BR, Davis MD, Gibson LE, Drage LA. Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases. Arch Dermatol 2003; 139:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/17\">",
"      Klein KL, Pittelkow MR. Tissue plasminogen activator for treatment of livedoid vasculitis. Mayo Clin Proc 1992; 67:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/18\">",
"      Deng A, Gocke CD, Hess J, et al. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 2006; 142:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/19\">",
"      Sauer GC. Pentoxifylline (Trental) therapy for the vasculitis of atrophie blanche. Arch Dermatol 1986; 122:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/20\">",
"      Sams WM Jr. Livedo vasculitis. Therapy with pentoxifylline. Arch Dermatol 1988; 124:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/21\">",
"      Hsiao GH, Chiu HC. Low-dose danazol in the treatment of livedoid vasculitis. Dermatology 1997; 194:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/22\">",
"      Juan WH, Chan YS, Lee JC, et al. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy. Br J Dermatol 2006; 154:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/23\">",
"      Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol 2004; 51:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/24\">",
"      Magy N, Algros MP, Racadot E, et al. [Liveoid vasculopathy with combined thrombophilia: efficacy of iloprost]. Rev Med Interne 2002; 23:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/25\">",
"      Rustin MH, Bunker CB, Dowd PM. Chronic leg ulceration with livedoid vasculitis, and response to oral ketanserin. Br J Dermatol 1989; 120:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/26\">",
"      Tuchinda C, Leenutaphong V, Sudtim S, Lim HW. Refractory livedoid vasculitis responding to PUVA: a report of four cases. Photodermatol Photoimmunol Photomed 2005; 21:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/27\">",
"      Lee JH, Choi HJ, Kim SM, et al. Livedoid vasculitis responding to PUVA therapy. Int J Dermatol 2001; 40:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6103/abstract/28\">",
"      Winkelmann RK, Schroeter AL, Kierland RR, Ryan TM. Clinical studies of livedoid vasculitis: (segmental hyalinizing vasculitis). Mayo Clin Proc 1974; 49:746.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4684 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-DA0D917308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6103=[""].join("\n");
var outline_f5_61_6103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Livedoid changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Atrophie blanche",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HYPERCOAGULABLE RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Excluding connective tissue diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Excluding known hypercoagulability risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Address hypercoagulability risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Empiric therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Antiplatelet therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Other treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4684\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4684|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/37/12887\" title=\"picture 1\">",
"      Livedoid vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/62/28644\" title=\"picture 2\">",
"      Atrophie blanche on foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/32/17926\" title=\"picture 3\">",
"      Atrophie blanche skin changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/8/27791\" title=\"picture 4\">",
"      Ulcerations LV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=related_link\">",
"      Diagnostic evaluation of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_61_6104="AV dissociation tutorial";
var content_f5_61_6104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1092px;\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Atrioventricular dissociation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 124px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Independent activation of the atria and ventricles results in no fixed relationship between the P waves (arrows) and the QRS complexes; the PR intervals are variable in a random fashion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6104=[""].join("\n");
var outline_f5_61_6104=null;
var title_f5_61_6105="Treatment of hemorrhoids";
var content_f5_61_6105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hemorrhoids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/61/6105/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/61/6105/contributors\">",
"     Ronald Bleday, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/61/6105/contributors\">",
"     Elizabeth Breen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/61/6105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/61/6105/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/61/6105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/61/6105/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/61/6105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhoids are normal vascular structures in the anal canal. However, they are often the source of a variety of problems. The cardinal features of hemorrhoidal disease include bleeding, anal pruritus, prolapse, and pain due to thrombosis. Although these symptoms may strongly suggest the diagnosis, confirmation by flexible sigmoidoscopy, anoscopy, or colonoscopy should be performed in patients who present with bleeding. Colonoscopy is generally recommended in older patients to exclude more serious underlying disease (eg, malignancy).",
"   </p>",
"   <p>",
"    A variety of over-the-counter preparations is available for the treatment of hemorrhoids, and patients often seek medical attention only after these modalities have failed. Thus, patients presenting to their physicians probably represent a group with relatively severe disease.",
"   </p>",
"   <p>",
"    Several options are available for the treatment of symptomatic hemorrhoids, and most patients will have relief with conservative or minimally invasive approaches. Surgery is successful for initial therapy in selected patients, in those whose symptoms are refractory to more conservative measures, and in those who have developed complications.",
"   </p>",
"   <p>",
"    This topic review will discuss the conservative, minimally invasive, and surgical treatments of hemorrhoids. The pathogenesis, classification (ie, grading), and clinical manifestations of this disorder is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=see_link\">",
"     \"Overview of hemorrhoids\"",
"    </a>",
"    .) The AGA guideline for the diagnosis and treatment of hemorrhoids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/1\">",
"     1",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA website at",
"    <a class=\"external\" href=\"file://www.gastrojournal.org/article/S0016-5085(04)00354-3/abstract\">",
"     www.gastrojournal.org/article/S0016-5085(04)00354-3/abstract",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF INTERNAL HEMORRHOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internal hemorrhoids have been graded across a spectrum of severity, which has proven useful for guiding treatment options (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I: The hemorrhoids do not prolapse",
"     </li>",
"     <li>",
"      Grade II: The hemorrhoids prolapse upon defecation but reduce spontaneously",
"     </li>",
"     <li>",
"      Grade III: The hemorrhoids prolapse upon defecation and must be reduced manually",
"     </li>",
"     <li>",
"      Grade IV: The hemorrhoids are prolapsed and cannot be reduced manually",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    External hemorrhoids are not graded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONSERVATIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative measures are successful for most patients with symptomatic hemorrhoids and bleeding, irritation, pruritus, or thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adding fiber to the diet may be beneficial for patients with bleeding from hemorrhoids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A meta-analysis of seven controlled trials found a significant and consistent benefit from fiber supplementation in improving bleeding (RR 0.50, 95% CI 0.28-0.68) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/3\">",
"     3",
"    </a>",
"    ]. In an illustrative study, supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    for six weeks was associated with improvement in bleeding compared to untreated controls [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/5\">",
"     5",
"    </a>",
"    ]. In a later trial, 50 patients with bleeding internal hemorrhoids were randomized to receive either a commercially available fiber preparation (Plantago Ovata) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/6\">",
"     6",
"    </a>",
"    ]. Endoscopy was performed before and after treatment. After 15 days of treatment, those who had received fiber supplementation had significantly fewer bleeding episodes and a reduction in the number of congested and friable hemorrhoidal cushions seen on endoscopy. Hemorrhoidal prolapse was not affected by fiber supplementation.",
"   </p>",
"   <p>",
"    Commercially available fiber supplements are available. Many contain either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    . Neither has been shown to have a particular advantage over the other in treating hemorrhoidal disease. Treatment should aim at a dose of 20 to 30",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    For patients who are unwilling to take fiber supplements, a detailed listing of the fiber content of various foods can be helpful (",
"    <a class=\"graphic graphic_table graphicRef82094 \" href=\"UTD.htm?17/1/17438\">",
"     table 1",
"    </a>",
"    ). Because fiber has other salutary effects, is safe to use, and may help to prevent recurrence, we recommend continued augmentation of fiber in the diet indefinitely.",
"   </p>",
"   <p>",
"    In Europe, hydroxyethylrutoside, an oral micronized flavonoid compound (Daflon, Les Laboratoires Servier, Gidy, France) has been used to treat hemorrhoidal disease. Some studies found that it reduced acute and recurrent hemorrhoidal attacks, including those in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/7-11\">",
"     7-11",
"    </a>",
"    ], as well as postoperative bleeding following surgical hemorrhoidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/12\">",
"     12",
"    </a>",
"    ]. However, many of the studies had important methodological limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/13\">",
"     13",
"    </a>",
"    ]. How hydroxyethylrutoside acts is uncertain; it improves venous tone, microvascular permeability, lymphatic activity, and microcirculatory nutritive flow [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Irritation and pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritation and pruritus associated with hemorrhoids can be treated with a variety of analgesic creams,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    suppositories, and warm sitz baths. These treatments, particularly hydrocortisone, should not be used for longer than one week since side effects may occur, such as contact dermatitis with analgesic creams or mucosal atrophy with steroid creams [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15110?source=see_link\">",
"     \"Approach to the patient with anal pruritus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sitz baths also help to relieve irritation and pruritus. They should be used in warm water two to three times per day. Their effectiveness may in part be related to relaxation of the internal anal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/17\">",
"     17",
"    </a>",
"    ]. A commercially available portable bowl allows for their use in the workplace.",
"   </p>",
"   <p>",
"    The benefit of fiber for irritation and pruritus is less well established than for bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/3\">",
"     3",
"    </a>",
"    ]. Fiber supplementation may relieve pruritus related to fecal soilage since the bulking effect of fiber may reduce leakage of liquid stool. There is no evidence that spicy foods worsen irritation and pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Thrombosed hemorrhoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organization and resorption of clot occurs within several days following thrombosis of internal or external hemorrhoids. It is important to appreciate, however, that thrombosis often occurs in grade III-IV internal hemorrhoids. These hemorrhoids usually persist after the conservative therapies outlined above, and may require definitive treatment. Treatment of acute thrombosis of internal hemorrhoids is usually conservative. Rare exceptions are patients who develop concomitant thrombosis of external and internal hemorrhoids (sometimes seen after childbirth) and who have severe pain in whom hemorrhoidectomy may be required.",
"   </p>",
"   <p>",
"    Thrombosed external hemorrhoids can cause excruciating pain, and patients will often present acutely (",
"    <a class=\"graphic graphic_picture graphicRef72916 \" href=\"UTD.htm?14/30/14831\">",
"     picture 1",
"    </a>",
"    ). In such cases, surgical evacuation of the hemorrhoid with excision of the skin overlying the thrombosed hemorrhoid can produce immediate relief. As an alternative, oral and topical analgesics, stool softeners, and sitz baths may provide adequate relief until spontaneous resolution occurs. Other conservative approaches have also been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small series suggested that topical 0.5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      ointment may provide temporary analgesia by reducing internal anal sphincter spasm [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/19\">",
"       19",
"      </a>",
"      ]. This dose may be associated with side-effects such as headache. A lower dose of nitroglycerin has been used in patients with anal fissures [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"       \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A small controlled trial suggested a benefit of topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized, placebo-controlled trial involving 30 patients found that a single intrasphincteric injection of botulinum toxin significantly reduced pain intensity within 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Topical steroids have not been well evaluated for effectiveness in treating thrombosed hemorrhoids. If used, some experts suggest applying cream rather than using suppositories. Steroid cream should be applied twice a day for no more than seven days. The cream may shrink the hemorrhoids and relieve the associated pruritus. Long term use should be avoided because of potential thinning of perianal and anal mucosa and increasing risk of injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link\">",
"       \"General principles of dermatologic therapy and topical corticosteroid use\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of rectal pathology among patients who present with a thrombosed external hemorrhoid is unknown. Following resolution of symptoms, it is reasonable to suggest a sigmoidoscopy if this has not been previously performed. A colonoscopy can be considered in patients with risk factors for colorectal cancer or in those older than 50 in whom it serves the added purpose of screening for colorectal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OFFICE BASED PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have continued symptoms despite the measures outlined above may be candidates for a minimally invasive technique developed for treating hemorrhoids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/4\">",
"     4",
"    </a>",
"    ]. Evacuation of thrombosed external or internal hemorrhoids may be performed in the office. The other minimally invasive techniques described below are generally used to treat",
"    <strong>",
"     internal",
"    </strong>",
"    hemorrhoids. Patients with grade IV internal hemorrhoids and some with grade III require more definitive surgical treatment. More aggressive treatment may also be preferred for patients who develop thrombosis, and is required for those presenting with a strangulated hemorrhoid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     External hemorrhoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Except in the case of thrombosis, external hemorrhoids do not usually require minimally invasive or surgical therapy. Patients seen within 72 hours of thrombosis may benefit from surgical evacuation for pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/4\">",
"     4",
"    </a>",
"    ]. However, after 48 hours, organization of the thrombus and amelioration of symptoms generally obviates the need for surgical evacuation.",
"   </p>",
"   <p>",
"    However, some surgeons advocate that such patients should undergo excision of the hemorrhoids to prevent recurrent thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19912?source=see_link&amp;anchor=H96135888#H96135888\">",
"     \"Outpatient and surgical procedures for hemorrhoids\", section on 'Evacuation of thrombosis and excision of external hemorrhoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Internal hemorrhoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the minimally invasive techniques used to treat internal hemorrhoids are ambulatory procedures associated with minimal morbidity. The principle of most of these therapies is to remove or to cause sloughing of excess hemorrhoidal tissue. Healing and scarring fixes the residual tissue to the underlying anorectal muscular ring. Examples of these treatments include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rubber band ligation",
"     </li>",
"     <li>",
"      Infrared coagulation",
"     </li>",
"     <li>",
"      Bipolar diathermy (Bicap)",
"     </li>",
"     <li>",
"      Laser photocoagulation",
"     </li>",
"     <li>",
"      Sclerotherapy",
"     </li>",
"     <li>",
"      Cryosurgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dilation of the internal sphincter has also been advocated. The rationale for this approach is that a hypertensive internal sphincter underlies the development of symptomatic hemorrhoids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the success of this treatment may be similar to the other modalities, and may result from the submucosal hemorrhage and scar formation associated with dilation.",
"   </p>",
"   <p>",
"    Some of these techniques may be better suited for particular hemorrhoidal problems. However, the choice among them often depends upon the availability of local expertise. A meta-analysis of 18 trials observed the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical hemorrhoidectomy was more effective than dilation or band ligation for preventing recurrent symptoms. However, rubber band ligation was associated with fewer complications and pain than surgery.",
"     </li>",
"     <li>",
"      Rubber band ligation was associated with a better response than sclerotherapy.",
"     </li>",
"     <li>",
"      Patients treated with sclerotherapy or infrared coagulation were more likely to require further therapy than those treated with rubber-band ligation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these findings, it was suggested that the optimal treatment for symptomatic grade I to III hemorrhoids unresponsive to conservative measures was rubber band ligation.",
"   </p>",
"   <p>",
"    However, another meta-analysis of five trials comparing the efficacy and side effects of infrared coagulation, injection sclerotherapy, and rubber band ligation came to different conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/25\">",
"     25",
"    </a>",
"    ]. Although recurrent symptoms were less common in patients undergoing rubber band ligation, the higher incidence of posttreatment pain compared to infrared coagulation outweighed the superior efficacy of rubber band ligation.",
"   </p>",
"   <p>",
"    Thus, rubber band ligation may be superior to other nonsurgical techniques for preventing recurrent symptoms but, compared to infrared coagulation, may be associated with a higher incidence of side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rubber band ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubber band ligation is the most widely used technique for treatment of symptomatic internal hemorrhoids that are refractory to conservative treatment. This procedure has been available since the early 1960s and is effective, inexpensive, requires no anesthesia, is easy to perform, and only rarely causes serious complications. The technique may be used for first, second, and selected third degree hemorrhoids. Successful ligation results in thrombosis of the hemorrhoid, and the development of localized submucosal scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334683449\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques have been described for the application of rubber bands to the affected hemorrhoid. All utilize the same principles as the traditional forceps approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1104018191\">",
"    <span class=\"h4\">",
"     Forceps applicator",
"    </span>",
"    &nbsp;&mdash;&nbsp;After identifying the involved hemorrhoid through an anoscope, a rubber ring ligating drum with two rubber rings is placed into the anal canal. The internal hemorrhoid is grasped with forceps, and the excess tissue is pulled into the drum of the ligator. The rubber rings are then advanced down to the neck of the hemorrhoid. The bands need to be placed at least 5 mm above the dentate line to avoid placement onto somatically innervated tissue. Only one column of hemorrhoids is treated in a single session to minimize risk of tissue necrosis. However, the placement of as many as three bands in a single column may be safely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1104018000\">",
"    <span class=\"h4\">",
"     Endoscopic suction ligator",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative technique involves suction of the symptomatic hemorrhoid into the ligating drum, which is attached to an endoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The ring is deployed through a trigger passed through the biopsy channel of the endoscope. This approach may allow for adequate ligation with fewer treatment sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/30\">",
"     30",
"    </a>",
"    ]. A single-handed non-endoscopic ligating device (KilRoid, Astra Tech, AB, Molndal, Sweden) has also been used successfully, and is less expensive than the endoscopic device [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1104018136\">",
"    <span class=\"h4\">",
"     Wall suction ligator",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to the standard technique of using forceps is the single operator vacuum suction band ligator [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/32\">",
"     32",
"    </a>",
"    ]. The principles are the same but the rubber band ligator is attached to wall suction. The surgeon places the drum with the rubber band against the hemorrhoid. Suction pulls the hemorrhoid into the drum and the rubber band is deployed. The technical advantage is that the surgeon can hold the ligator and apply the band with one hand and hold the anoscope with the other unassisted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334683562\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the largest series to describe long-term outcomes of rubber band ligation included 805 patients who underwent 2114 ligations (median of two ligations in each patient) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/33\">",
"     33",
"    </a>",
"    ]. Excluding 104 patients who were lost to follow-up, treatment was considered successful in 71 percent (80 percent when considering patients who underwent repeated treatment after initial failure). Success rates were similar for all degrees of hemorrhoids. A higher failure rate was observed in patients who required four or more bands to be placed. The application of the rubber band using wall suction can be performed in fewer sessions compared with the standard forceps technique (1.2 versus 2 sessions) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334683464\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complication rate following rubber band ligation is low [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/26,33,35-37\">",
"     26,33,35-37",
"    </a>",
"    ]. The most frequent complication is pain, which occurs in approximately 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe pain can occur from misapplication of the band below the dentate line, or from associated spasm. Many patients complain of anal or rectal \"tightness\" after the procedure. Other complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed hemorrhage &ndash; Delayed hemorrhage can occur when the rubber band dislodges, typically two to four days after application or with ulceration and mucosal sloughing, which can occur five to seven days after the procedure.",
"     </li>",
"     <li>",
"      Hemorrhoidal thrombosis &ndash; Hemorrhoids distal to the rubber band ligation thrombose, leading to pain or a palpable mass.",
"     </li>",
"     <li>",
"      Localized infection &ndash; Localized infection or abscesses can occur at the site of band ligation. Persistent pain, fever, or foul smelling rectal drainage may signal the onset of infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sepsis &ndash; Fulminant sepsis after hemorrhoid ligation is rare [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bipolar, infrared, and laser coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;These techniques involve the application of bipolar current or infrared or laser light to cause coagulation and necrosis, which leads to fibrosis in the submucosal layer. They are generally effective for grade I to II internal hemorrhoids and each has its advocates [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Infrared coagulation may be associated with more frequent recurrences than rubber band ligation, but may have fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specialized needles can be used to inject sclerosing agents directly into the hemorrhoidal tissue. A variety of injected sclerosing agents is effective for grade I and II internal hemorrhoids. Examples include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/21/43346?source=see_link\">",
"     sodium morrhuate",
"    </a>",
"    , 5 percent phenol, and hypertonic saline. The sclerosant causes an intense inflammatory reaction, destroying redundant submucosal tissue associated with hemorrhoidal prolapse. Hemorrhoidal sclerotherapy may be less effective than rubber band ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cryosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of special probes cooled with liquid nitrogen causes freezing, necrosis, and subsequent fixation of the hemorrhoidal cushion. However, band ligation, photocoagulation with laser or infrared light, and electrical coagulation with Bicap have supplanted cryosurgery, which may be associated with a higher rate of complication and less patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laser hemorrhoidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhoidectomy using the ND:YAG or carbon dioxide laser has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. However, these approaches do not appear to offer a significant advantage to other approaches and the required equipment is expensive. Furthermore, serious complications have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Doppler-guided hemorrhoidal artery ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A specially designed proctoscope (called the Moricorn) housing a Doppler transducer has been approved for the treatment of internal hemorrhoids. The device can identify hemorrhoidal arteries and permits their ligation with sutures. A report on its use in 116 patients with internal hemorrhoids demonstrated improvement in pain, prolapse and bleeding in 96, 78, and 95 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continued symptoms despite conservative or minimally invasive measures usually require surgical intervention. In addition, surgery is the initial treatment of choice in patients with symptomatic grade IV hemorrhoids or those who have strangulated internal hemorrhoids. It may also be required for symptomatic grade III hemorrhoids and in patients who present with thrombosed hemorrhoids.",
"   </p>",
"   <p>",
"    A medical position statement issued by the American Gastroenterological Association suggests that surgery should be recommended only for a small minority of patients with any of the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure of medical and nonoperative therapy",
"     </li>",
"     <li>",
"      Symptomatic third-degree, fourth-degree, or mixed internal and external hemorrhoids",
"     </li>",
"     <li>",
"      Symptomatic hemorrhoids in the presence of a concomitant anorectal condition that requires surgery",
"     </li>",
"     <li>",
"      Patient preference after discussion of the treatment options with the referring physician and surgeon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Techniques for the operative treatment of hemorrhoids include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Closed hemorrhoidectomy",
"     </li>",
"     <li>",
"      Open hemorrhoidectomy with excision and ligation",
"     </li>",
"     <li>",
"      Stapled hemorrhoidectomy",
"     </li>",
"     <li>",
"      Lateral internal sphincterotomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These procedures usually require general or spinal anesthesia. However, selected patients may tolerate the procedure with sedation and a local anesthetic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Closed hemorrhoidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closed hemorrhoidectomy, or a modification of the technique, is the most common surgical procedure performed for internal hemorrhoids. For the standard closed hemorrhoidectomy, an elliptical incision is made starting on the external hemorrhoidal tissue and extending proximally across the dentate line to the superior extent of the hemorrhoidal column. Care is taken to make the ellipse relatively narrow, and to remove only the redundant anoderm and hemorrhoidal tissue. The defect is closed with a continuous absorbable suture. Usually three hemorrhoidal columns are treated. This technique is successful in 95 percent of cases and has a low rate of wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Open hemorrhoidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;To reduce the risk of infection, some surgeons advocate excision and ligation without mucosal closure. However, one study compared open hemorrhoidectomy to a modified closed approach (\"semi-open\") in 300 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/47\">",
"     47",
"    </a>",
"    ]. The semi-open technique was associated with more rapid healing and a lower incidence of postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Stapled hemorrhoidectomy (stapled hemorrhoidopexy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intraluminal circular stapling device has been developed as an alternative to conventional surgical hemorrhoidectomy. The device excises a circumferential column of mucosa and submucosa from the upper anal canal, thus reducing the hemorrhoids back into the anal canal and fixing them in position. It also interrupts part of the hemorrhoidal blood supply thereby decreasing vascularity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. It is not appropriate for treatment of external hemorrhoids.",
"   </p>",
"   <p>",
"    The stapled hemorrhoidectomy device is being used more commonly in patients with bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolapsing internal hemorrhoids who have failed rubber band ligation. Its role as primary therapy is still being determined. The following illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three systematic reviews concluded that stapled hemorrhoidopexy was less effective than conventional surgery and was associated with a higher long-term risk of hemorrhoid recurrence and prolapse [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/51-53\">",
"       51-53",
"      </a>",
"      ]. There is also a higher incidence of additional operations and tenesmus with stapled hemorrhoidopexy as compared with conventional hemorrhoidectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/53\">",
"       53",
"      </a>",
"      ]. On the other hand, the stapled approach was associated with significantly less pain, a shorter inpatient stay, operative time, and time to return to normal activity [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A controlled trial comparing stapled hemorrhoidectomy to rubber band ligation as primary therapy suggested that stapled hemorrhoidectomy was associated with more pain and minor morbidity, although it had a significantly lower risk of recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial of stapled hemorrhoidopexy versus hemorrhoidectomy, the procedures were equally effective in preventing recurrence after one year [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/54\">",
"       54",
"      </a>",
"      ]. Patients undergoing hemorrhoidectomy were more likely to have symptomatic relief from the hemorrhoids (69 versus 44 percent with hemorrhoidopexy), but had significantly greater postoperative pain.",
"     </li>",
"     <li>",
"      A retrospective evaluated outcomes after a median of 73 months in 291 patients with Grade II or IV hemorrhoids who underwent stapled hemorrhoidopexy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/55\">",
"       55",
"      </a>",
"      ]. Moderate hemorrhoid-related symptoms were reported in 25 percent while 9 percent reported severe symptoms. Recurrence was reported in 18 percent of whom 21 patients (7 percent of the original cohort) underwent reoperation. Patient satisfaction was 90 percent overall.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One role for stapled hemorrhoidopexy may be for patients seeking a less painful alternative to conventional surgery if the higher risk of recurrence and prolapse are considered an acceptable tradeoff. However, because it is relatively new, its disadvantages may not yet be fully understood. Furthermore, occasional but significant complications are still being reported and the device is expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. Persistent post-defecation pain affects a small percentage of patients; one study suggested that such symptoms may respond rapidly and completely to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lateral internal sphincterotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have internal hemorrhoids associated with high resting internal anal sphincter pressures may benefit from this procedure. It should be avoided in those who have normal resting sphincter pressure and should be primarily reserved for patients with concomitant fissure disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Complications of hemorrhoidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main complications following a standard closed hemorrhoidectomy include urinary retention, urinary tract infection, fecal impaction, and delayed hemorrhage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary retention following hemorrhoidectomy is observed in as many as 30 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/62\">",
"       62",
"      </a>",
"      ]. Many of these patients remain asymptomatic, although some require urinary catheterization. Limiting postoperative fluids may reduce the need for catheterization (from 15 to less than 4 percent in one study) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/63\">",
"       63",
"      </a>",
"      ]. Warm sitz baths and pain medication also may lessen urinary retention and reduce the need for catheterization.",
"     </li>",
"     <li>",
"      Urinary tract infection develops in approximately 5 percent of patients after anorectal surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/64\">",
"       64",
"      </a>",
"      ], possibly secondary to occult urinary retention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"       \"Urinary tract infection associated with urethral catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Delayed hemorrhage, probably due to sloughing of the primary clot, develops in 1 to 2 percent of patients; it usually occurs 7 to 16 days postoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/64\">",
"       64",
"      </a>",
"      ]. No specific treatment is effective for preventing this complication, which usually requires a return to the operating room for suture ligation.",
"     </li>",
"     <li>",
"      Fecal impaction after a hemorrhoidectomy is associated with postoperative pain and opiate use. Most surgeons recommend stimulant laxatives, stool softeners, and bulk fiber to prevent this problem. Should impaction develop, manual disimpaction with anesthesia may be required.",
"     </li>",
"     <li>",
"      Infection is surprisingly uncommon after hemorrhoid surgery. A submucosal abscess occurs in less than 1 percent of cases and severe fasciitis or necrotizing infections are rare [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other complications include sphincter damage (which is rare), wound dehiscence (which is common but usually of no clinical consequence), and stricture formation (approximate incidence of 1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20439434\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE PAIN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain following hemorrhoidectomy is nearly universal and may in part be due to spasm of the internal sphincter. Because of the frequency of this problem, most patients are given a local injection of a long-acting anesthetic, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , during the procedure to provide postoperative local pain control. In a review of prospective trials that assessed analgesia following hemorrhoidectomy, perianal infiltration with a long-acting local anesthetic provided significant pain relief, whether given alone or with oral analgesics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other end of procedure options have been evaluated in small randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, placebo-controlled trial of 18 patients found that topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ointment (2 percent) applied to the perianal region three times daily for seven days postoperatively was significantly more effective than placebo in reducing pain and the need for prescription narcotics [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/66\">",
"       66",
"      </a>",
"      ]. The mechanism of benefit is presumably related to relaxation of the internal anal sphincter.",
"     </li>",
"     <li>",
"      A second randomized trial that compared injection of botulinum toxin to injection of placebo in 30 patients found that botulinum toxin was associated with significant reductions in postoperative pain and the time of healing [",
"      <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial postoperative therapy for pain control consists of oral analgesics such as nonsteroidal antiinflammatory drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/65\">",
"     65",
"    </a>",
"    ]. Opioids may be given if pain is not well controlled but carry the potential adverse effects of inducing constipation and possibly worsening the pain.",
"   </p>",
"   <p>",
"    A bulk fiber supplement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased dietary fiber and fluid intake will help reduce postoperative constipation and pain upon defecation. A sensation of \"tightness\" after the procedure can usually be alleviated with a warm sitz bath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/15/41202?source=see_link\">",
"       \"Patient information: Hemorrhoids (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=see_link\">",
"       \"Patient information: Hemorrhoids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     AMERICAN SOCIETY OF COLON AND RECTAL SURGEONS GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society of Colon and Rectal Surgeons (ASCRS) has issued guidelines for the treatment of hemorrhoids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/61/6105/abstract/4\">",
"     4",
"    </a>",
"    ]. These guidelines are available online at",
"    <span class=\"nowrap\">",
"     www.fascrs.org/physicians/practice_parameters/.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We",
"    agree with the guidelines issued by the ASCRS, with modifications for grade III hemorrhoids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend dietary management consisting of adequate fluid and fiber intake as the primary medical treatment",
"      <strong>",
"      </strong>",
"      of symptomatic hemorrhoids",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Conservative treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with medically refractory grades I and II hemorrhoids, we recommend an office-based procedure for initial surgical treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend rubber band ligation as the initial office-based procedure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Office based procedures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Rubber band ligation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a single symptomatic grade III hemorrhoid, the authors perform a rubber band ligation. If two or three hemorrhoidal columns are symptomatic, we perform a surgical excision. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with grade IV hemorrhoids or who have combined internal and external hemorrhoids with significant prolapse, we recommend surgical excision (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical hemorrhoidectomy is indicated for patients who fail or are unable to tolerate office-based procedures. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Office based procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with thrombosed external hemorrhoids, we recommend either observation (oral and topical analgesics, stool softeners, and sitz baths) or excision of overlying skin and clot evaluation, if possible, within 72 hours of onset of symptoms (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      )",
"      <strong>",
"       .",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Thrombosed hemorrhoids'",
"      </a>",
"      above.) Definitive treatment is an excision of the external hemorrhoid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19912?source=see_link&amp;anchor=H96135888#H96135888\">",
"       \"Outpatient and surgical procedures for hemorrhoids\", section on 'Evacuation of thrombosis and excision of external hemorrhoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend perianal infiltration with a long-acting local anesthetic agent, either as a sole technique or as an adjunct to general or regional anesthesia, and a combination of oral analgesics (eg, non-steroidal anti-inflammatory,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ) for postoperative pain control (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20439434\">",
"       'Postoperative pain management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/1\">",
"      Clinical Practice Committee, American Gastroenterological Association. American Gastroenterological Association medical position statement: Diagnosis and treatment of hemorrhoids. Gastroenterology 2004; 126:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/2\">",
"      Banov L Jr, Knoepp LF Jr, Erdman LH, Alia RT. Management of hemorrhoidal disease. J S C Med Assoc 1985; 81:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/3\">",
"      Alonso-Coello P, Guyatt G, Heels-Ansdell D, et al. Laxatives for the treatment of hemorrhoids. Cochrane Database Syst Rev 2005; :CD004649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/4\">",
"      Rivadeneira DE, Steele SR, Ternent C, et al. Practice parameters for the management of hemorrhoids (revised 2010). Dis Colon Rectum 2011; 54:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/5\">",
"      Moesgaard F, Nielsen ML, Hansen JB, Knudsen JT. High-fiber diet reduces bleeding and pain in patients with hemorrhoids: a double-blind trial of Vi-Siblin. Dis Colon Rectum 1982; 25:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/6\">",
"      Perez-Miranda M, Gomez-Cedenilla A, Le&oacute;n-Colombo T, et al. Effect of fiber supplements on internal bleeding hemorrhoids. Hepatogastroenterology 1996; 43:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/7\">",
"      Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology 1994; 45:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/8\">",
"      Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 1994; 45:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/9\">",
"      Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994; 45:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/10\">",
"      Buckshee K, Takkar D, Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynaecol Obstet 1997; 57:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/11\">",
"      Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids. Br J Surg 2000; 87:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/12\">",
"      Ho YH, Foo CL, Seow-Choen F, Goh HS. Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy. Br J Surg 1995; 82:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/13\">",
"      Alonso-Coello P, Zhou Q, Martinez-Zapata MJ, et al. Meta-analysis of flavonoids for the treatment of haemorrhoids. Br J Surg 2006; 93:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/14\">",
"      Wadworth AN, Faulds D. Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs 1992; 44:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/15\">",
"      Cusano F, Luciano S. Contact dermatitis from pramoxine. Contact Dermatitis 1993; 28:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/16\">",
"      Kawada A, Noguchi H, Hiruma M, et al. Fixed drug eruption induced by lidocaine. Contact Dermatitis 1996; 35:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/17\">",
"      Shafik A. Role of warm-water bath in anorectal conditions. The \"thermosphincteric reflex\". J Clin Gastroenterol 1993; 16:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/18\">",
"      Altomare DF, Rinaldi M, La Torre F, et al. Red hot chili pepper and hemorrhoids: the explosion of a myth: results of a prospective, randomized, placebo-controlled, crossover trial. Dis Colon Rectum 2006; 49:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/19\">",
"      Gorfine SR. Treatment of benign anal disease with topical nitroglycerin. Dis Colon Rectum 1995; 38:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/20\">",
"      Lund JN, Scholefield JH. A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure. Lancet 1997; 349:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/21\">",
"      Perrotti P, Antropoli C, Molino D, et al. Conservative treatment of acute thrombosed external hemorrhoids with topical nifedipine. Dis Colon Rectum 2001; 44:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/22\">",
"      Patti R, Arcara M, Bonventre S, et al. Randomized clinical trial of botulinum toxin injection for pain relief in patients with thrombosed external haemorrhoids. Br J Surg 2008; 95:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/23\">",
"      Lord PH. A day-case procedure for the cure of third-degree haemorrhoids. Br J Surg 1969; 56:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/24\">",
"      MacRae HM, McLeod RS. Comparison of hemorrhoidal treatments: a meta-analysis. Can J Surg 1997; 40:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/25\">",
"      Johanson JF, Rimm A. Optimal nonsurgical treatment of hemorrhoids: a comparative analysis of infrared coagulation, rubber band ligation, and injection sclerotherapy. Am J Gastroenterol 1992; 87:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/26\">",
"      Khubchandani IT. A randomized comparison of single and multiple rubber band ligations. Dis Colon Rectum 1983; 26:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/27\">",
"      Berkelhammer C, Moosvi SB. Retroflexed endoscopic band ligation of bleeding internal hemorrhoids. Gastrointest Endosc 2002; 55:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/28\">",
"      Su MY, Chiu CT, Wu CS, et al. Endoscopic hemorrhoidal ligation of symptomatic internal hemorrhoids. Gastrointest Endosc 2003; 58:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/29\">",
"      Fukuda A, Kajiyama T, Arakawa H, et al. Retroflexed endoscopic multiple band ligation of symptomatic internal hemorrhoids. Gastrointest Endosc 2004; 59:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/30\">",
"      Wehrmann T, Riphaus A, Feinstein J, Stergiou N. Hemorrhoidal elastic band ligation with flexible videoendoscopes: a prospective, randomized comparison with the conventional technique that uses rigid proctoscopes. Gastrointest Endosc 2004; 60:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/31\">",
"      Dickey W, Garrett D. Hemorrhoid banding using videoendoscopic anoscopy and a single-handed ligator: an effective, inexpensive alternative to endoscopic band ligation. Am J Gastroenterol 2000; 95:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/32\">",
"      Ramzisham AR, Sagap I, Nadeson S, et al. Prospective randomized clinical trial on suction elastic band ligator versus forceps ligator in the treatment of haemorrhoids. Asian J Surg 2005; 28:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/33\">",
"      Iyer VS, Shrier I, Gordon PH. Long-term outcome of rubber band ligation for symptomatic primary and recurrent internal hemorrhoids. Dis Colon Rectum 2004; 47:1364.",
"     </a>",
"    </li>",
"    <li>",
"     Suction vs forcep: band ligation for hemorrhoid treatment a prospective, randomized study www.cookmedical.com/esc/educationArticle.do?id=7408 (Accessed on October 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/35\">",
"      Scarpa FJ, Hillis W, Sabetta JR. Pelvic cellulitis: a life-threatening complication of hemorrhoidal banding. Surgery 1988; 103:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/36\">",
"      Wechter DG, Luna GK. An unusual complication of rubber band ligation of hemorrhoids. Dis Colon Rectum 1987; 30:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/37\">",
"      Marshman D, Huber PJ Jr, Timmerman W, et al. Hemorrhoidal ligation. A review of efficacy. Dis Colon Rectum 1989; 32:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/38\">",
"      Iwagaki H, Higuchi Y, Fuchimoto S, Orita K. The laser treatment of hemorrhoids: results of a study on 1816 patients. Jpn J Surg 1989; 19:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/39\">",
"      O'Connor, JJ. Infrared coagulation of hemorrhoids. Practical Gastroenterology 1986; 10:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/40\">",
"      Buls JG, Goldberg SM. Modern management of hemorrhoids. Surg Clin North Am 1978; 58:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/41\">",
"      Hodgson WJ, Morgan J. Ambulatory hemorrhoidectomy with CO2 laser. Dis Colon Rectum 1995; 38:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/42\">",
"      Senagore A, Mazier WP, Luchtefeld MA, et al. Treatment of advanced hemorrhoidal disease: a prospective, randomized comparison of cold scalpel vs. contact Nd:YAG laser. Dis Colon Rectum 1993; 36:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/43\">",
"      Leff EI. Hemorrhoidectomy--laser vs. nonlaser: outpatient surgical experience. Dis Colon Rectum 1992; 35:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/44\">",
"      Gill JR, Morrow JS, West AB. Fatal hemorrhage following laser hemorrhoidectomy. J Clin Gastroenterol 1994; 19:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/45\">",
"      Morinaga K, Hasuda K, Ikeda T. A novel therapy for internal hemorrhoids: ligation of the hemorrhoidal artery with a newly devised instrument (Moricorn) in conjunction with a Doppler flowmeter. Am J Gastroenterol 1995; 90:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/46\">",
"      Ferguson JA, Mazier WP, Ganchrow MI, Friend WG. The closed technique of hemorrhoidectomy. Surgery 1971; 70:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/47\">",
"      Reis Neto JA, Quilici FA, Cordeiro F, Reis J&uacute;nior JA. Open versus semi-open hemorrhoidectomy: a random trial. Int Surg 1992; 77:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/48\">",
"      Mehigan BJ, Monson JR, Hartley JE. Stapling procedure for haemorrhoids versus Milligan-Morgan haemorrhoidectomy: randomised controlled trial. Lancet 2000; 355:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/49\">",
"      Rowsell M, Bello M, Hemingway DM. Circumferential mucosectomy (stapled haemorrhoidectomy) versus conventional haemorrhoidectomy: randomised controlled trial. Lancet 2000; 355:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/50\">",
"      Peng BC, Jayne DG, Ho YH. Randomized trial of rubber band ligation vs. stapled hemorrhoidectomy for prolapsed piles. Dis Colon Rectum 2003; 46:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/51\">",
"      Nisar PJ, Acheson AG, Neal KR, Scholefield JH. Stapled hemorrhoidopexy compared with conventional hemorrhoidectomy: systematic review of randomized, controlled trials. Dis Colon Rectum 2004; 47:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/52\">",
"      Jayaraman S, Colquhoun PH, Malthaner RA. Stapled versus conventional surgery for hemorrhoids. Cochrane Database Syst Rev 2006; :CD005393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/53\">",
"      Giordano P, Gravante G, Sorge R, et al. Long-term outcomes of stapled hemorrhoidopexy vs conventional hemorrhoidectomy: a meta-analysis of randomized controlled trials. Arch Surg 2009; 144:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/54\">",
"      Nystr&ouml;m PO, Qvist N, Raahave D, et al. Randomized clinical trial of symptom control after stapled anopexy or diathermy excision for haemorrhoid prolapse. Br J Surg 2010; 97:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/55\">",
"      Ceci F, Picchio M, Palimento D, et al. Long-term outcome of stapled hemorrhoidopexy for Grade III and Grade IV hemorrhoids. Dis Colon Rectum 2008; 51:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/56\">",
"      Cheetham MJ, Mortensen NJ, Nystrom PO, et al. Persistent pain and faecal urgency after stapled haemorrhoidectomy. Lancet 2000; 356:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/57\">",
"      Cheetham MJ, Cohen CR, Kamm MA, Phillips RK. A randomized, controlled trial of diathermy hemorrhoidectomy vs. stapled hemorrhoidectomy in an intended day-care setting with longer-term follow-up. Dis Colon Rectum 2003; 46:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/58\">",
"      Koh DC, Cheong DM, Wong KS. Stapled haemorrhoidectomy: bothersome staple line bleeding. Asian J Surg 2005; 28:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/59\">",
"      Cirocco WC. Life threatening sepsis and mortality following stapled hemorrhoidopexy. Surgery 2008; 143:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/60\">",
"      Thaha MA, Irvine LA, Steele RJ, Campbell KL. Postdefaecation pain syndrome after circular stapled anopexy is abolished by oral nifedipine. Br J Surg 2005; 92:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/61\">",
"      Arabi Y, Alexander-Williams J, Keighley MR. Anal pressures in hemorrhoids and anal fissure. Am J Surg 1977; 134:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/62\">",
"      Lyngdorf P, Frimodt-M&oslash;ller C, Jeppesen N. Voiding disturbances following anal surgery. Urol Int 1986; 41:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/63\">",
"      Bailey HR, Ferguson JA. Prevention of urinary retention by fluid restriction following anorectal operations. Dis Colon Rectum 1976; 19:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/64\">",
"      Bleday R, Pena JP, Rothenberger DA, et al. Symptomatic hemorrhoids: current incidence and complications of operative therapy. Dis Colon Rectum 1992; 35:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/65\">",
"      Joshi GP, Neugebauer EA, PROSPECT Collaboration. Evidence-based management of pain after haemorrhoidectomy surgery. Br J Surg 2010; 97:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/66\">",
"      Silverman R, Bendick PJ, Wasvary HJ. A randomized, prospective, double-blind, placebo-controlled trial of the effect of a calcium channel blocker ointment on pain after hemorrhoidectomy. Dis Colon Rectum 2005; 48:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/61/6105/abstract/67\">",
"      Patti R, Almasio PL, Muggeo VM, et al. Improvement of wound healing after hemorrhoidectomy: a double-blind, randomized study of botulinum toxin injection. Dis Colon Rectum 2005; 48:2173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1382 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-197.136.42.3-BBD4CCF919-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6105=[""].join("\n");
var outline_f5_61_6105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF INTERNAL HEMORRHOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONSERVATIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Irritation and pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Thrombosed hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OFFICE BASED PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      External hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Internal hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rubber band ligation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H334683449\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1104018191\">",
"      Forceps applicator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1104018000\">",
"      Endoscopic suction ligator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1104018136\">",
"      Wall suction ligator",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H334683562\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H334683464\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bipolar, infrared, and laser coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cryosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laser hemorrhoidectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Doppler-guided hemorrhoidal artery ligation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Closed hemorrhoidectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Open hemorrhoidectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Stapled hemorrhoidectomy (stapled hemorrhoidopexy)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lateral internal sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Complications of hemorrhoidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20439434\">",
"      POSTOPERATIVE PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      AMERICAN SOCIETY OF COLON AND RECTAL SURGEONS GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1382\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1382|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/30/14831\" title=\"picture 1\">",
"      Thrombosed external hemorrhoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1382|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/1/17438\" title=\"table 1\">",
"      Dietary fiber content of frequently consumed foods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=related_link\">",
"      Anal fissure: Clinical manifestations, diagnosis, prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15110?source=related_link\">",
"      Approach to the patient with anal pruritus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19912?source=related_link\">",
"      Outpatient and surgical procedures for hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=related_link\">",
"      Overview of hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=related_link\">",
"      Patient information: Hemorrhoids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/15/41202?source=related_link\">",
"      Patient information: Hemorrhoids (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_61_6106="Classification systems for truncus arteriosus";
var content_f5_61_6106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Classification systems for truncus arteriosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 718px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left: Type I to IV, by Collett and Edwards (1949). Of note, type IV is no longer&nbsp;considered a variant of truncus arteriosus but rather it is categorized as pulmonary atresia.&nbsp;Right: Types A1 to A4, by Van Praagh and Van Praagh (1965).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cabalka AK, Edwards WD, Dearani JA. Truncus arteriosus. In: Heart Disease in Infants, Children, and Adolescents Including the Fetus and Young Adult, 7th ed, Allen HD, Shaddy RE, Driscoll DJ, Feltes TF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6106=[""].join("\n");
var outline_f5_61_6106=null;
var title_f5_61_6107="Differential Dx factitious somatoform and malingering disorders";
var content_f5_61_6107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of somatoform disorder, factitious disorder, and malingering",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Somatoform disorder",
"      </td>",
"      <td class=\"subtitle1\">",
"       Factitious disorder",
"      </td>",
"      <td class=\"subtitle1\">",
"       Malingering",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Physical mechanism",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psychological factor",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Voluntary/conscious",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Obvious goal",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6107=[""].join("\n");
var outline_f5_61_6107=null;
var title_f5_61_6108="Comprehensive diabetic foot exam";
var content_f5_61_6108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key components of the diabetic foot exam",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inspection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Dermatologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin status: color, thickness, dryness, cracking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sweating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infection: check between toes for fungal infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ulceration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calluses/blistering: hemorrhage into callus?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Musculoskeletal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deformity, eg, claw toes, prominent metatarsal heads, Charcot joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Muscle wasting (guttering between metatarsals)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurological assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        10-g monofilament +&nbsp;one of the following four",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibration using 128-Hz tuning fork",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pinprick sensation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ankle reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        VPT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vascular assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foot pulses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABI, if indicated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Boulton, AJM, Armstrong, DG, Albert, ST, et al. Comprehensive Foot Examination and Risk Assessment: A report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008; 31:1679. Copyright &copy;2008 American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6108=[""].join("\n");
var outline_f5_61_6108=null;
var title_f5_61_6109="PTCL path";
var content_f5_61_6109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histology, immunophenotype, and genetic features of the peripheral T cell lymphomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Entity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immunophenotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genetic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angioimmunoblastic T cell lymphoma",
"       </td>",
"       <td>",
"        Polymorphous infiltrate of small to large atypical lymphocytes with prominent arborizing high endothelial venules. Expanded populations of follicular dendritic cells can be detected with CD21 staining.",
"       </td>",
"       <td>",
"        <p>",
"         Express CD3 and CD4; sometimes express BCL-6 and CD10.",
"        </p>",
"        <p>",
"         May lose a subset of pan-T cell antigens (ie, CD2, CD3, CD5, CD7).",
"        </p>",
"       </td>",
"       <td>",
"        TCR genes are rearranged in 75 to 90 percent; immunoglobulin heavy chains are rearranged in 25 percent. Epstein-Barr virus and human herpes virus-6 genomes may be present in reactive B cells.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteropathy-associated T cell lymphoma",
"       </td>",
"       <td>",
"        <p>",
"         Tumor cells are of variable size and morphology.",
"        </p>",
"        <p>",
"         The adjacent \"normal\" mucosa often demonstrates signs of celiac disease.",
"        </p>",
"       </td>",
"       <td>",
"        Typically express CD3 and do not express CD4; most cases also CD8 negative. Large cells within the tumor infiltrate are frequently CD30 positive.",
"       </td>",
"       <td>",
"        <p>",
"         TCR beta gene is clonally rearranged. Many patients have an HLA haplotype associated with celiac disease.",
"        </p>",
"        <p>",
"         50 to 60 percent have complex segmental amplification of the 9q34 region.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extranodal NK/T cell lymphoma; nasal type",
"       </td>",
"       <td>",
"        Polymorphous lymphoid infiltrate of variable morphology that invades the vascular walls, often producing extensive fibrinoid necrosis.",
"       </td>",
"       <td>",
"        Express CD2, cytoplasmic CD3, CD56, and cytotoxic granule proteins, and are negative for surface CD3.",
"       </td>",
"       <td>",
"        Clonal Epstein-Barr virus genomes are virtually always present. TCR and immunoglobulin genes are usually germline.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatosplenic T cell lymphoma",
"       </td>",
"       <td>",
"        Malignant cells accumulate within the sinusoids of the liver, spleen, or bone marrow.",
"       </td>",
"       <td>",
"        Express CD2, surface CD3, CD7, and CD16, and do not express CD4, CD5, or CD8. Express gamma/delta TCR or alpha/beta TCR.",
"       </td>",
"       <td>",
"        Cytogenetics demonstrating isochrome 7q supports the diagnosis, but is not essential.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subcutaneous panniculitis-like T cell lymphoma",
"       </td>",
"       <td>",
"        Subcutaneous infiltrate of atypical lymphocytes involving the fat lobules, but typically sparing the septae, overlying dermis, and epidermis.",
"       </td>",
"       <td>",
"        Express CD3, CD8, and the alpha/beta TCR, but are negative for CD4, CD56, and TCR gamma. Strong expression of the cytotoxic granule proteins. Expression of CD2, CD5, and/or CD7 is variable.",
"       </td>",
"       <td>",
"        Clonal TCR rearrangements are present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaplastic large cell lymphoma T/null cell type",
"       </td>",
"       <td>",
"        Composed of large cells with horseshoe-shaped or embryoid nuclei, prominent nucleoli, and abundant cytoplasm. Often shows a cohesive growth pattern.",
"       </td>",
"       <td>",
"        Homogeneous and strong expression of CD30 in a membrane and golgi pattern. Usually express one or more T cell antigens (ie, CD2, CD3, CD5, CD7).",
"       </td>",
"       <td>",
"        Two distinct subtypes: ALK positive (detected by immunostains or molecular genetics) and ALK negative.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral T cell lymphoma; not otherwise specified.",
"       </td>",
"       <td>",
"        Mixture of small and large atypical cells.",
"       </td>",
"       <td>",
"        Varies greatly from case to case, but always demonstrates expression of one or more of the pan-T antigens (ie, CD2, CD3, CD5, CD7). Roughly half of cases lose a T cell antigen (ie, CD2, CD3, CD5, CD7).",
"       </td>",
"       <td>",
"        While the majority have cytogenetic abnormalities, none is specific.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TCR: T cell receptor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6109=[""].join("\n");
var outline_f5_61_6109=null;
var title_f5_61_6110="Translation HAV genome";
var content_f5_61_6110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatitis A viral RNA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 427px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Terrault NA, Wright TL. Viral Hepatitis A through G. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, WB Saunders, Philadelphia, 1988. p.1123. Copyright &copy; 1988 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6110=[""].join("\n");
var outline_f5_61_6110=null;
var title_f5_61_6111="Peau d orange pattern in NS";
var content_f5_61_6111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Picture showing \"peau d'orange\" pattern in arm of patient with nephrogenic system fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arm from this patient with nephrogenic systemic fibrosis reveals thickening of the skin and erythematous plaques that have coalesced to form a \"peau d'orange\" pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Shawn E Cowper, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_61_6111=[""].join("\n");
var outline_f5_61_6111=null;
